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Doxorubicin (Dox) is a widely used anthracycline antibiotic used to treat a 
number of hematological and solid tumor cancers. Dosage however, is limited due to its 
toxic effects in healthy tissues. Negative consequences include myotoxicity in skeletal 
muscle, which may limit mobility and activities of daily living. Doxorubicin increases the 
formation of reactive oxygen species, which triggers apoptosis in the tumor and healthy 
tissue.  Skeletal muscle undergoes apoptosis in response to Dox treatment, via the 
activation of the cleaved caspase-3 and its downstream target, poly(ADP-ribose) 
polymerase.   Creatine monohydrate (Cr), a naturally occurring chemical, when taken 
exogenously, can improve athletic performance.  Recently, it has been shown that Cr can 
positively impact several diseases and act as a antioxidant, capable of scavenging free 
radicals and reducing apoptosis.  Purpose: To determine the effect of two types of Cr 
feeding and Dox administration on skeletal muscle apoptotic proteins at two separate 
time points. Methods: Ten week old male Sprague-Dawley rats were randomly assigned 
to one of six groups: control + saline (Con-Sal, n=10), control + doxorubicin (Con-Dox, 
n=10), creatine 1 + saline (C1-Sal, n=10), creatine 1 + doxorubicin (C1-Dox, n=10), 
creatine 2 + saline (C2-Sal, n=10), creatine 2 + doxorubicin (C2-Dox, n=10). Animals 
were fed for four weeks and were injected with a bolus 15 mg/kg i.p. injection of Dox or 
Sal and sacrificed either 1-day or 3-days post injection.  Post injection, the extensor 
digitorum longus (EDL), soleus (SOL), and diaphragm (DIA) were excised and Western 
blotting for expression of cleaved PARP, caspase-3, and cleaved caspase-3 was 
	 	 	
conducted.  Creatine concentration was also analyzed using a commercially available 
assay kit.  Results: A main drug effect was observed, with increased levels of apoptosis 
observed in the 1-day EDL, SOL, and in the 3-day EDL.  Equally, a main drug effect was 
observed, with decreased caspase-3 levels in the 3-day SOL, and cleaved PARP levels in 
the 3-day DIA.  There was a diet effect, with increased cleaved PARP levels in the 1-day 
EDL, SOL, and cleaved caspase-3 levels in the 3-day EDL.  An equal diet effect was 
detected, with decreased caspase-3 levels in the 1-day EDL and cleaved caspase-3 levels 
in the 1-day SOL and DIA.  The 1-day SOL had lower creatine concentration with Dox 
administration and the 3-day EDL had decreased Cr concentrations with both Dox 
administration and Cr feeding. Conclusion: Doxorubicin had the largest impact on 
apoptosis in the EDL, suggesting Dox’s effects on apoptosis may differ between tissue.  
Creatine concentration in the EDL was lower in animals receiving Dox, and this was not 
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INTRODUCTION TO THE STUDY 
Background 
 Cancer is a group of diseases characterized by the uncontrolled growth and spread 
of abnormal cells.  If this abnormal growth is left uncontrolled, it can result in death.  
According to Siegel, Miller, and Jemal (2019), as of January 1, 2016, more than 15.5 
million Americans have a history of cancer.  About 1.7 million new cancer cases are 
expected to be diagnosed in 2018, with about 609,640 Americans dying from the disease 
(Siegel et al., 2019).  The overall age-adjusted cancer death rate has improved, decreasing 
from 215 deaths per 100,000 in 1991 to 159 deaths per 100,000 in 2015 which is a 26% 
decrease (Siegel et al., 2019).  The improvement in age-adjusted death is largely due to 
advanced screening, increased awareness, and improved treatments (Siegel et al., 2019).  
Improvement in age-adjusted deaths should be interpreted with caution as they do not 
always indicate progress against cancer.  In fact, cancer is still one of the leading causes 
of death and disease in the US, costing Americans $80.2 billion dollars in 2015 (Siegel et 
al., 2019).   
 Currently, there are three types of cancer treatment options available: surgery, 
radiation, and pharmacological therapy.  These treatments can be used alone or in most 
cases, in combination.  Surgery is the removal of a tumor and can be used to diagnose 
cancer, determine how far it has spread, stop growth and ultimately, the primary method 
to “cure” the patient.  Radiation is the use of high energy waves/particles to destroy or 
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severely damage a tumor.  Pharmacological therapy is the use of medication to destroy or 
slow growth of a tumor.  Medications can include chemotherapy, targeted therapy, 
immunotherapy, hormone therapy, and other supportive medications.   
 Pharmacological therapy, specifically chemotherapy, is often used as part of a 
patient’s cancer treatment.  Doxorubicin (Dox), or Adriamycin, is an anthracycline 
antibiotic chemotherapy drug synthesized from the soil fungus Streptomyces.  
Doxorubicin is commonly used to treat a variety of cancers including breast, ovarian, 
bladder, lung, thyroid, and stomach cancers.  Doxorubicin dosing is dependent on a 
patient’s height, weight, general health, type of cancer, and has a lifetime maximal dose.  
A lifetime maximal dose means a patient can only receive a set amount of Dox in their 
lifetime and exceeding that dose can result in death from causes other than cancer.  
Doxorubicin is typically administered via intravenous injection (although in some 
cancers, such as peritoneal tumors, an intraperitoneal injection is used) and exerts its anti-
cancer effects by halting the cell cycle in the tumor, preventing division.  Doxorubicin 
halts the cell cycle by three main mechanisms, (1) intercalation into DNA disrupting 
replication, (2) disruption of topoisomerase-II-mediated DNA repair, and (3) generation 
of free radicals, which damages cellular membranes, DNA and proteins (Thorn et al., 
2011).  Along with its tumor damaging capabilities, Dox has the capacity to damage 
health tissue, specifically (to the research conducted in our lab), cardiac tissue and 
skeletal muscle.  
 Doxorubicin administration may result in chronic cardiotoxicity, with an 
estimated incidence of about 1.7% (Von Hoff et al., 1979) and is usually evident within 
30 days of administration.  Doxorubicin cardiotoxicity is a result of increased oxidative 
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stress (increased levels of reactive oxygen species and lipid peroxidation) (Takemura & 
Fujiwara, 2007), decreased levels of antioxidants and sulfhydryl groups (Singal, Li, 
Kumar, Danelisen, & Illiskovic, 2000), inhibition of nucleic acid and protein synthesis, 
release of vasoactive amines (Bristow et al., 1980), altered adrenergic function, and 
decreased expression of cardiac-specific genes (Tong, Ganguly, & Singal, 1991).   
 In skeletal muscle, Dox treatment decreased maximal twitch force in the extensor 
digitorum longus and soleus, as well as, increased fatigue in the soleus (Gilliam et al., 
2012; Hydock, Lien, Jensen, Schneider, & Hayward, 2011; van Norren et al., 2009).  
Equally, intraperitoneal injections of Dox decreased fiber bundle diameter and absolute 
force production in the murine diaphragm (Bonifati et al., 2000).  Further, rodents 
injected with Dox showed loss of myofibrillar organization with interstitial edema 
(Doroshow, Tallent, & Schechter, 1985), nucleolar segregation, and altered distribution 
of the perinucleolar chromatin in hindlimb skeletal muscle (Merski, Daskal, & Busch, 
1978).  The increased skeletal muscle fatigue and loss of skeletal muscle size described 
above resulted from increased apoptotic activation (Hilder, Carlson, Haystead, Krebs, & 
Graves, 2005), mediated through increased Dox-induced ROS formation (Timolati et al., 
2006) and activation of caspases (Wang et al., 2004).   
 Currently there is a push to uncover nutraceutical interventions that can mitigate 
Dox-induced myotoxicity.  Studies have shown that exercise mitigates Dox-induced 
myotoxcity through the impedance of the Dox-induced ROS production and protease 
activation (Smuder, Kavazis, Min, & Powers, 1985), preservation of maximal twitch 
force, attenuation of skeletal muscle fatigue (Bredahl, Pfannenstiel, Quinn, Hayward, & 
Hydock, 2016) and reduction in chemotherapy-induced muscle fatigue (Fairman, Hyde, 
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& Focht, 2016; Van Moll, Schep, Vreugdenhil, Savelberg, & Husson, 2016).  However, 
exercise as an intervention is problematic because adherence significantly decreases in 
patients that are in treatment and in those who have just finished treatment (Courneya et 
al., 2007; Markes, Brockow, & Resch, 2006; McNeely et al., 2006; Mutrie et al., 2007).  
Equally, research has shown that exercise preconditioning is protective against Dox-
induced weakness and fatigue (Kavazis, Smuder, & Powers, 1985; Smuder et al., 1985) 
however, it has been reported that 30-40% of newly diagnosed cancer patients meet the 
minimum recommendations for physical activity, which makes this intervention not a 
viable option.  This leads to a further search for a nutraceutical intervention that can 
mitigate Dox-induced myotoxicity and have a high rate of adherence in patients whom 
exercise adherence is typically low.  Supplementing the diet with creatine as a 
nutraceutical intervention to mitigate Dox-induced myotoxicity is a possibility.   
Creatine monohydrate (Cr) is perhaps one of the most widely used nutraceuticals 
ingested in an attempt to improve athletic performance. A large amount of research has 
been done on Cr supplementation, in efforts to delineate its sport-specific effects. It is 
hypothesized that Cr acts through a number of pathways and appears to be most effective 
in short-term, high-intensity physical activities.  However, the past decade has showed 
that the use of Cr for therapeutic purposes has received increasing attention (Gualano, 
Artioli, Poortmans, & Lancha Junior, 2009).  Creatine supplementation is beneficial in a 
large number of muscular, neurological, and cardiovascular diseases (Bender et al., 2007; 
Felber et al., 2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999; 
Mazzini et al., 2001; Neubauer et al., 1999; Sharov et al., 1987; Stout, Eckerson, May, 
Coulter, & Bradley-Popovich, 2001; Tarnopolsky et al., 2004; Tarnopolsky, 2007; 
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Vorgerd et al., 2000; Wyss & Schulze, 2002;); however, less documented are the effects 
of Cr on Dox-induced skeletal muscle dysfunction, and there is a lack of research on 
possible mechanisms leading to improvements in Dox-induced skeletal muscle 
dysfunction.   
To the author’s knowledge, Bredahl and Hydock (2017) published the only study 
to examine the effects of Cr on Dox-induced skeletal muscle dysfunction. In this ex vivo 
study, Bredahl and Hydock (2017) found that incubating the soleus and extensor 
digitorum longus in creatine monohydrate prior to Dox treatment attenuated Dox-induced 
fatigue in both the soleus and the extensor digitorum longus.  Although mechanisms 
contributing to the results were not analyzed in the aforementioned study, it is postulated 
that Cr acted as an antioxidant, decreasing ROS formation (Lawler & Powers, 1998; 
Sestili et al., 2006; Sestili et al., 2009), and preserving muscle function. In light of the 
above findings, and given that Dox treatment increases apoptosis, it was imperative to 
examine what effect Cr supplementation had on the apoptosis in Dox treated animals, 
specifically the apoptotic markers cleaved poly ADP ribose polymerase (PARP) and 
cleaved caspase-3, in skeletal muscle from Dox treated animals.  It is important to begin 
to elucidate the benefits Cr supplementation has on Dox-induced skeletal muscle toxicity.   
Statement of Purpose 
 The purpose of the current study was to examine the effects doxorubicin and two 
types of creatine monohydrate feeding, had on cleaved (PARP), caspase-3, and cleaved 
caspase-3, at 1-day post injection and 3-days post injection, in the extensor digitorum 






H1 Dox alone will increase apoptosis in the SOL, EDL, and DIA.   
 
H2 Both types of Cr supplemented diets alone will have no effect on, 
apoptosis,at either 1-day or 3-day post-injection time points.  
 
H3 Cr will attenuate Dox-induced apoptosis, with a higher percent Cr feeding 
having a greater attenuation than a lower percent Cr feeding in the SOL, 
EDL, and DIA.  
 
H4 Dox alone will increase apoptosis more at the 3-days post injection time 
point, than at 1-day post injection time point in the SOL, EDL, and DIA.  
 
H5 The 4% Cr supplemented diet will have a greater impact on attenuating 
Dox-induced increases in apoptosis, than the 2% Cr supplemented diet, at 
the 3-days post injection time point in the SOL, EDL, and DIA. 
 
H6 Both types of Cr feeding will attenuate Dox-induced increases in apoptosis 
to a greater extent in the EDL, than to either the SOL or DIA at both the 1-
day and 3-days post injection time points.   
 
H7 Free Cr and phosphocreatine levels will be greater in the 4% Cr 
supplemented diet, than the 2% Cr supplemented diet, in the SOL, EDL, 
and DIA, at both 1-day and 3-days post injection time points. 
 
Need for Study 
 It is well documented that chemotherapy treatment increases muscle fatigue and 
weakness leading to decreases in activities of daily living (ADL).  Specifically, patients 
treated with Dox exhibit disrupted skeletal muscle function resulting in debilitating 
muscle weakness (Gilliam et al., 2012).  Any treatment or intervention that can reduce or 
mitigate chemotherapy-induced muscle fatigue and weakness will improve a patients 
ADL, and overall quality of life.  Animal studies have shown that exercise can mitigate 
chemotherapy-induced muscle fatigue, weakness, and cardiovascular dysfunction 
(Fairman, et al., 2016; Van Moll et al., 2016); however, adherence to exercise programs 
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during and post chemotherapy is very low, and a low percentage of cancer patients are 
active upon entering a treatment program (Courneya et al., 2007; Markes et al., 2006; 
McNeely et al., 2006; Mutrie et al., 2007). Therefore, it is important to find interventions 
that improve chemotherapy-induced muscle fatigue, weakness, and ADL and have the 
potential for greater adherence.  Creatine supplementation has the potential to be such an 
intervention.  Creatine can be taken daily, either mixed in liquid or food, and is generally 
well tolerated.  Although not researched in human populations receiving chemotherapy, 
in healthy populations, creatine supplementation has been shown to increase aerobic 
performance and anaerobic capacity (Chwalbinska-Moneta, 2003).  In light of these 
findings, there was rationale for investigating what effect creatine may have on muscular 
fatigue and weakness in patients receiving chemotherapy as a way of improving ADL’s 
and attenuating Dox myotoxicity.   
Preliminary Findings 
Recent research was conducted on twenty rodents that were randomly assigned to 
receive either a bolus 15 mg/kg Dox injection (Dox, n=10) or an equivalent sterile saline 
injection (Con, n=10) and sacrificed 1-day post injection.  Animals were anesthetized 
with sodium pentobarbital (50 mg/kg).  After the rodent was completely anesthetized (i.e. 
no response with a tail pinch) the left soleus (SOL), left extensor digitorum longus (EDL) 
and diaphragm (DIA) were removed, trimmed, weighed, flash frozen in liquid nitrogen, 
and stored at -800C for biochemical analysis.  The tissues were homogenized, and 
Western blotting analysis was conducted on the SOL, EDL, and DIA for the presence of 




One-day Extensor Digitorum Longus  
Apoptotic Protein Levels 
 
In the EDL (Figure 1), an unpaired t-test revealed no significant effects in cleaved 
PARP levels, p>0.05 (Figure 1A).  There was a significant drug effect, with the Dox 
group exhibiting lower caspase-3 levels, p<0.05 (Figure 1B). 
One-day Soleus Apoptotic  
Protein Levels 
 
In the SOL (Figure 2) no main effects were observed (p>0.05) for cleaved PARP 
(Figure 2A) and caspase-3 (Figure 2B). 
One-day Diaphragm Apoptotic  
Protein Levels 
 
In the DIA (Figure 3) no main effects were observed (p>0.05) for cleaved PARP 














Figure 1.1-day EDL apoptotic protein levels, (A) cleaved PARP and (B) caspase-3.  
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con = control 
saline, n=10; Dox = control doxorubicin, n=10; Values are mean ± SEM. 




Figure 2. 1-day SOL apoptotic protein levels, (A) cleaved PARP and (B) caspase-3. 
SOL = soleus, kDa = kilodalton, OD = optical density, Con = control saline, n=10; Dox = 
control doxorubicin, n=10; Values are mean ± SEM. 











Figure 3. 1-day DIA apoptotic protein levels, (A) cleaved PARP and (B) caspase-3. 
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con = control saline, n=10; 
Dox = control doxorubicin, n=10; Values are mean ± SEM. 















Figure 1B showed that Dox treatment significantly affected caspase-3 levels in 
the EDL.  Equally, although not significant, Figure 1B shows a trend for higher cleaved 
PARP levels with Dox administration.  The changes in caspase-3 and cleaved PARP 
levels suggest an increase in apoptosis in the EDL with Dox.  In the SOL and DIA, 
although not significant, there were increased levels of cleaved PARP with Dox 
administration, once again, suggesting that apoptosis may be increased in the SOL and 
DIA with Dox.  These results suggest that in the EDL, SOL, and DIA, Dox 
administration may increase apoptosis.  
To further explore the effects of Dox treatment on apoptotic protein expression, 
adding the protein cleaved caspase-3 to the study will be important to see if the decrease 
in whole caspase-3 expression (observed DIA and EDL in the pilot study) is coupled with 
an increase in cleaved caspase-3 expression.  In light of these findings, further 
exploration is warranted to examine what effect different doses of creatine monohydrate 
may have on cleaved PARP, caspase-3, and cleaved caspase-3 in the SOL, EDL, and 
DIA.  Equally, adding an additional time point (3-days post injection) will broaden our 
understanding of how Dox may impact apoptosis, via measuring the changes in cleaved 
PARP, caspase-3, and cleaved caspase-3 levels. The data gathered will be useful in 
beginning to illuminate what role creatine monohydrate may have in reducing Dox-










REVIEW OF THE LITERATURE 
Doxorubicin 
Doxorubicin (Dox) or Adriamycin, and sometimes Rubex, is an Anthracycline 
antibiotic, synthesized from the soil fungus Streptomyces.  Doxorubicin is among the 
most commonly used drugs for treating a wide range of human cancers, including 
leukemias, Wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast 
carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, 
gastric carcinoma, Hodgkin’s disease, malignant lymphoma, and lung cancer.  
Doxorubicin is administered via intravenous injection through a central line or peripheral 
venous line over several minutes and is given in 21-day intervals (Johnson-Arbor & 
Dubey, 2017).  Doxorubicin dosing is calculated using body surface area derived from 
the Du Bois and Du Bois formula published in 1916 (Pouliquen et al., 2011), and due to 
its induction of cardiotoxicity and heart failure (Chatterjee, Zhang, Honbo, & Karliner, 
2010), has a maximum lifetime dose not to exceed 450 mg/m2 (Rahman, Yusuf, & Ewer, 
2007).   
 Although not completely elucidated, the proposed mechanisms that explain Dox’s 
tumor killing activity are redox cycling in the mitochondria, topoisomerase inhibition, 
oxidative stress, and apoptosis signaling (Wang et al., 2004).  By far the most damaging 
activity of Dox is its redox cycling, and will be furthered explained in the section, 
‘Doxorubicin – Redox Cycling’. 
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Reactive Oxygen Species 
 The utilization of molecular oxygen by mammals leads to the formation of 
reactive oxygen species (ROS).  Reactive oxygen species are small molecules that are 
short-lived and highly reactive (Halliwell, 2011). ROS can be generated endogenously 
during mitochondrial oxidative phosphorylation, or via interactions with exogenous 
sources.  The main ROS consist of hydrogen peroxide (H2O2), hydroxyl radical (HO•), 
nitric oxide (NO•), peroxyl radical (ROO•), peroxynitrite anion (ONOO-), and 
superoxide anion (O2•-) and consist of a radical and non-radical oxygen species formed 
by the partial reduction of oxygen.  Reactive oxygen species can be generated by both 
exogenous and endogenous stimuli.  Endogenous production occurs when electrons leak 
during mitochondrial electron transport chain activity (Dickinson & Chang, 2011). 
Superoxide is produced in complexes I and III of the electron transport chain, by NADPH 
oxidases, and via enzymatic activation of cytochrome P450 reductases (Bae, Oh, Rhee, & 
Yoo, 2011).  The powerful oxidant peroxynitrite anion (ONOO-) is formed when the 
superoxide anion (O2•-) reacts with the reactive nitrogen species (RNS) nitric oxide (NO•) 
(Dickinson & Chang, 2011). The superoxide anion (O2•-) can also be dismutated into 
oxygen (O2) and hydrogen peroxide (H2O2) by the antioxidant superoxide dismutase 
(SOD).  Once formed, H2O2 can be used in the inflammatory process or form a hydroxyl 
radical (OH•) (Kehrer & Klotz, 2015). The hydroxyl radical is highly reactive, and the 
cell avoids formation by detoxifying H2O2 via the antioxidant enzymes catalase and 
glutathione peroxidase (West & Marnett, 2006).  generation of ROS in cells exist in 
equilibrium with a wide variety of antioxidant defenses.   
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The antioxidant defenses include the enzymatic scavenger’s superoxide dismutase 
(SOD), catalase, glutathione peroxidase and peroxiredoxins (Halliwell, 2011).  There are 
also non-enzymatic scavengers including vitamins C and E, glutathione (GSH), lipoic 
acid, carotenoids and iron chelators (Halliwell, 2011). Normal ROS production is 
important and essential for the regulation of normal physiological functions, including, 
cell cycle progression and proliferation, differentiation, migration, and cell death 
(Covarrubias, Hernandez-Garcia, Schnabel, Salas-Vidal, & Castro-Obregon, 2008).  
Equally, ROS play a role in the immune system and in maintenance in redox balance 
(Zhang et al., 2016).  Lastly, ROS have been implicated in the activation of various 
cellular signaling pathways and transcription factors (Zhang et al., 2016). If this control 
tightly ROS, antioxidant system becomes dysregulated, oxidative stress results. 
 Halliwell (2011) defined oxidative stress as “a serious imbalance between the 
generation of ROS and antioxidant defenses in favor of ROS, causing excessive oxidative 
damage”.   Oxidative stress or excess levels of cellular ROS can cause fragmentation of 
amino acids in proteins, alteration of DNA bases, and lipid peroxidation to membranes 
and organelles such as the mitochondria (Halliwell, 2011).  Equally, oxidative stress has 
been implicated in the development of pathologies, (Trachootham, Alexandre, & Huang, 
2009), neurodegeneration (Andersen, 2004; Shukla, Mishra, & Pant, 2011), 
atherosclerosis, diabetes (Paravicini & Touyz, 2006), aging (Haigis & Yankner, 2010), 
and the promotion of tumor metastasis through gene activation (Ishikawa et al., 2008).  






 Apoptosis is a specific distinct form of cell death, that occurs normally during 
development and aging and as a homeostatic mechanism to maintain cell populations in 
tissues.  There are a wide variety of both physiological and pathological stimuli that can 
trigger apoptosis, and not all cells will necessarily die at the same rate or as a result of the 
same stimuli.  For example, chemotherapy drugs or radiation treatment may damage 
DNA in some cells leading to apoptosis via the p53-dependent pathway, where other cells 
do not share the same fate (Yang, Niepel, Mitchison, & Sorger, 2010).   
 Although, it is not the focus of this dissertation study, it is worth noting that an 
alternative to apoptosis is necrosis, the degradative process that occurs after cell death, 
which some do not consider necrosis to be a viable form of cell death. However, there is 
some overlap in the apoptotic/necrotic pathways, with the distinction depending on the 
nature of the cell death signal, tissue type, developmental stage of the tissue, and the 
physiologic milieu (Fiers, Beyaert, Declercq, & Vandenabeele, 1999; Zeiss, 2003).  
 Apoptosis can be triggered via two main pathways, the extrinsic and intrinsic 
pathways, and in some instances the two pathways can influence one another (Igney & 
Krammer, 2002). There is an additional pathway that involves T-cell mediated 
cytotoxicity and perforin-granzyme-dependent killing of the cell (Kaspar et al., 2001). As 
an overview of apoptosis, regardless of the pathway signaled (extrinsic, intrinsic, T-cell), 
they all converge on the same terminal which is initiated by the cleavage of caspase-3.  
Caspase-3 cleavage results in DNA fragmentation, degradation of cytoskeletal/nuclear 
proteins, cross linking of proteins, formation of apoptotic bodies, expression of ligands 
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for phagocytic cell receptors and then the uptake of the degraded parts by phagocytic 
cells (Elmore, 2007).   
 The extrinsic apoptotic pathway involves transmembrane receptor-mediated 
interactions, specifically the tumor necrosis factor receptor gene family death receptors 
Fas receptor or FasR (Locksley, Killeen, & Lenardo, 2001).  The binding of the Fas 
ligand (FasL) to FasR, initiates the extrinsic apoptotic pathway, transmitting the death 
signal from the cell surface into the intracellular signaling pathway.  Fas ligand is a 
transmembrane protein that binds to it receptor FasR.  Fas ligands are formed when they 
are cleaved by matrix metalloproteinase (MMP-7) and enter circulation.  Fas ligands then 
binds to the FasR on the cell surface which results in the binding of the adapter protein 
Fas-associated death domain (FADD) to the death domain of Fas, via its own death 
domain.  FADD then associates, via dimerization, with the death domain of procaspase-8 
(Wajant, 2002).  This forms the death-inducing signaling complex (DISC), which 
activates procaspase-8 (Kischkel et al., 1995).  Activated caspase-8 will trigger the 
execution phase of apoptosis (Kischkel et al., 1995).   
 Unlike the extrinsic apoptotic pathway that is initiated by ligand/receptor 
interaction, the intrinsic apoptotic pathway is triggered by non-receptor-mediated stimuli 
that produces an intracellular signal that acts directly on targets directly within the cell.  
The non-receptor-mediated stimuli can either act in a positive or negative fashion.  A 
negative stimulus is a withdrawal of factors that suppress the pathway, thereby triggering 
the pathway.  A positive stimulus increases the apoptotic pathway, an example being free 
radical production, which is relevant to the current study.  Regardless of the non-
receptor-mediated stimuli (positive or negative) the result are changes in the inner 
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mitochondrial membrane: opening of the mitochondrial permeability pore, loss of 
transmembrane potential and release of two groups of normally sequestered pro-apoptotic 
proteins from the intermembrane space to the cytosol (Saelens et al., 2004).   
 The first group of pro-apoptotic proteins that are released from the intermembrane 
space via non-receptor-mediated stimuli are cytochrome c, Smac/DIABLO, and the 
serine protease HtrA2/Omi (Du, Fang, Li, Y., Li, L., & Wang, 2000; Garrido et al., 
2006).  The second group of pro-apoptotic proteins are apoptosis-inducing factor, 
endonuclease G and CAD, which are released later than the first group of pro-apoptotic 
proteins, after the cell has committed to die.  The above mentioned apoptotic 
mitochondrial events (i.e., the mitochondrial release of the pro-apoptotic proteins) are 
controlled and regulated by Bcl-2 family of proteins and the tumor suppressor p53 
regulation of Bcl-2, with the mechanisms not being entirely understood (Cory & Adams, 
2002; Schuler & Green, 2001). The Bcl-2 family of proteins is quite large, containing 25 
genes that have been identified in the Bcl-2 family.  The Bcl-2 proteins govern 
mitochondrial permeability and determine if the cell will commit to apoptosis or abort 
(Cory & Adams, 2002).   
 The last apoptotic pathway to briefly discuss is the T-cell mediated and involves 
the cytotoxic T lymphocytes (CTLs).  Upon binding to the target cell, the CTLs secrete 
the transmembrane pore-forming molecule perforin, which then releases its cytoplasmic 
granules (granzyme A and granzyme B) through the pore into the target cell (Pardo et al., 
2004; Trapani & Smyth, 2002).  Once inside, granzyme A and B act as proteases, which 
end up activating procaspase-10, directly activating caspase-3 and signaling the induction 
of the execution phase of apoptosis (Sakahira, Enari, & Nagata, 1998). 
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 All of the pathways (extrinsic, intrinsic, T-cell), once signaled, end with 
triggering of the execution pathway, which is the final apoptotic pathway.  In the 
execution pathway, the execution caspases are activated, which activate cytoplasmic 
endonucleases that begin the process of nuclear and cytoskeletal protein degradation, 
nuclear material breakdown, cytoskeletal reorganization, chromatin condensation, and 
disintegration of the cell into apoptotic bodies (Sakahira et al., 1998; Slee, Adrain, & 
Martin, 2001).  The main execution caspases (or sometimes referred to as effector 
caspases) are caspase-3, caspase-6, and caspase-7, which cleave various substrates such 
as poly (ADP-ribose) polymerase (PARP), alpha fodrin, NuMA, and others, which cause 
the morphological changes described above (Slee et al., 2001).   
 Of all the execution caspases, caspase-3 is considered to be imperative for 
apoptosis to occur.  When there is a disruption in mitochondrial function (loss of 
transmembrane potential, permeability transition and release of cytochrome c), as with 
Dox therapy, the result is activation of apoptosis-activating factor 1 (AIF) and caspase -9, 
leading to the processing of pro-caspase-3 (Kluck et al., 1997; Li et al., 1997; Pan, 
O’Rourke, & Dixit, 1998; Reed, 1997; Zou, Henzel, Liu, Lutschg, & Wang, 1997). 
Worth noting is that in caspase-9 knockout mice, caspase-3 fails to activate in the 
absence of caspase-9, giving evidence that caspase-9 is a critical upstream activator of 
caspase-3 (Cheng et al., 1997). Once caspase-3 is activated, downstream death substrates 
are cleaved, including poly (ADP-ribose) polymerase (PARP) (Janicke, Ng, Sprengart, & 
Porter, 1998).  Caspase-3 can also amplify the upstream death cascade, increasing 
cytochrome c release by cleaving Bcl-2 converting it from an anti-apoptotic to a pro-
apoptotic protein (Cheng et al., 1997).  In closing, apoptosis is a fundamental and 
	 20 
	
complex biological process that enables an organism to kill and remove unwanted cells 
during animal development, normal homeostasis and disease (Jacobson, Weil, & Raff, 
1997; Thompson, 1995).   
Reactive Oxygen Species and Apoptosis 
 As stated in the previous section, ROS are small molecules that are short-lived 
and highly reactive (Halliwell, 2011).  They can be oxygen derived like superoxide anion 
(O2•-) and the hydroxyl radical (OH•), or non-radical molecules like hydrogen peroxide 
(H2O2).  As stated earlier, apoptosis is a tightly regulated and highly conserved process of 
cell death during which a cell undergoes self-destruction (Kerr, Wyllie, & Currie, 1972).  
It is also worth mentioning that apoptosis is an essential process that multicellular 
organisms use to eliminates damaged cells, neutralize cells with DNA damage, and 
protect against carcinogenesis (Fulda, Gorman, Hori, & Samali, 2010; Pallepati & 
Averill-Bates, 2012).   
 Normal, low dose ROS production has been linked to a cell survival response, via 
the ROS activation of the tumor suppressor protein p53 (Carafoli & Lehninger, 1971).  
p53, a key protein that regulates the cellular stress response, either inducing cell cycle 
arrest for cell repair, or if damage is beyond repair, triggering cell death via apoptosis 
(Guerrero-Hernandez, Gallegos-Gomez, Sanchez-Vazquez, & Lopez-Mendez, 2014). At 
rest, p53 is maintained at low cellular levels and rises during cell stress (Guerrero-
Hernandez et al., 2014).  As p53 levels rise during elevated cellular stress and if the 
cellular damage is too severe, p53 can regulate apoptosis transcriptionally by 
downregulating pro-survival proteins and upregulating pro-apoptotic proteins (Guerrero-
Hernandez et al., 2014). The activation of the pro-apoptotic proteins can also induce the 
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activation of both the intrinsic apoptotic pathway (i.e., changes to the mitochondrial 
membrane) and the extrinsic apoptotic pathway (i.e., death receptor activation).   
 Reactive oxygen species stimulation of the intrinsic apoptotic pathway results in 
the formation of the permeability transition pore, and produces mitochondrial outer 
membrane permeabilization, resulting in the mitochondria-to-cytosol translocation of 
cytochrome c, AIF, or Smac/DIABLO, that trigger the caspase cascade that results in cell 
death (Redza-Dutordoir & Averill-Bates, 2016).  ROS can trigger the intrinsic pathway 
via a number of mechanisms include directly oxidizing mitochondrial proteins, inducing 
lipid peroxidation, and damaging mitochondrial DNA (mtDNA) (Redza-Dutordoir & 
Averill-Bates, 2016).  The mtDNA damage can results in decreased transcription of 
proteins essential in the electron transport chains.  The decrease in protein transcription 
disrupts respiratory chain function, which further increases ROS generation.  This leads 
to a disruption in mitochondrial membrane potential and impaired ATP synthesis; all of 
which will lead to apoptosis (Orrenius, Gogvadze, & Zhivotovsky, 2015).  Equally, ROS, 
particularly H2O2, can oxidize protein components of the mitochondrial permeability 
transition pore (MPTP), which will cause its formation of a pore in the mitochondrial 
membrane.  The formation of the pore causes mitochondrial membrane 
hyperpolarization, mitochondrial translocation of Bax and Bad, cytochrome c release, and 
the formation of the executioner caspase-3, 6, and 7 (Nie et al., 2008).   
 There is a reported link between the ROS production and the extrinsic apoptotic 
pathway.  More specifically there seems to be a link between ROS production and TNF-a 
activation, although this relationship is not completely understood.  TNF-a is an 
important regulator of the signaling network that promote either cell-survival or cell 
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death by apoptosis (Mahmood & Shukla, 2010). ROS are important in regulation of the 
TNF-R1 signaling pathway, and at high doses, ROS can trigger the TNF-R1 pathway to 
drive cell death (Mahmood & Shukla, 2010).  The extrinsic apoptotic death receptor 
Fas/FasL pathway can also be activated by the ROS H2O2 (Pallepati & Averill-Bates, 
2011). Pallepati and Averill-Bates, (2011) found that H2O2 caused up-regulation of FasL, 
and FADD translocation to the plasma membrane and caspase-8 activation in the HeLa 
cell line.  Equally in endothelial cells, human leukemia cells, and intestinal epithelial 
cells, H2O2 has been shown to increase mRNA levels of FasL and Fas and direct 
activation of caspase-8 and caspase-3 (Denning et al., 2002; Suhara et al., 1998; Zhuang, 
Demirs, & Kochevar, 2000).  Lastly, not well understood is the capacity for ROS to 
activate Fas and TNF-a which causes lipid raft formation, recruitment and activation of 
Nox. Activation of the Nox family of transmembrane proteins are an important source of 
ROS, and this increase in Nox-mediated ROS can feedback and further stimulate the 
death receptors Fas and TNF-a, furthering Nox family activation and ROS production 
(Zhang et al., 2007).  
 In closing, ROS at lower doses is important for proper cell survival responses, 
where they can induce cell cycle arrest to promote DNA repair and survival.  However, at 
higher doses ROS activate the death process such as apoptosis.  At these higher doses, 
ROS can directly activate the intrinsic mitochondrial apoptotic pathway through 
disrupting permeability of the mitochondrial membrane and through the extrinsic death 
receptor apoptotic pathway by activating certain death receptors.  Both ROS activated 
apoptotic pathways, intrinsic and extrinsic, lead to the activation of the execution 
pathway and cell death.  Doxorubicin, through the process of redox cycling, creates a 
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large quantity of ROS, and will increase the signaling of the intrinsic and extrinsic 
apoptotic pathways, increasing the rate of cell death in all cells where doxorubicin 
undergoes redox cycling. 
Doxorubicin and Redox Cycling 
 Oxidative stress is a widely recognized mechanism of Dox-induced toxicity 
(Wang et al., 2004).  The development of oxidative stress with Dox treatment is driven by 
two mechanisms, increased levels of ROS following Dox treatment and the 
downregulation of antioxidants enzymes following Dox administration.  The first 
mechanism, increased ROS levels, may result from different mechanisms including 1) 
decreased cellular antioxidant defenses, 2) disruption of the mitochondrial electron 
transport chain with subsequent electron leakage, and 3) the ability of Dox to undergo 
redox cycling and produce ROS (Zhao et al., 2010).  Dox redox cycling leading to ROS 
production is the most widely recognized mechanism by which oxidative stress increases 
with Dox administration.   
Redox cycling typically involves the reduction of a quinone molecule to form a 
semiquinone radical species (Hopkins, 2016) and occurs in the cytochrome P450 enzyme 
system and the mitochondrial electron transport chain.  The creation of ROS with Dox 
administration occurs when the semiquinone radical donates one of its electrons to 
molecular oxygen.  This donation reduces molecular oxygen to superoxide anion radical, 
and the semiquinone radical is oxidized back to the original quinone molecule.  This one-
electron reduction and oxidation cycle will continue and persist in the production of 
superoxide anion radicals and secondary reactive species such as hydrogen peroxide, 
hydroxyl radical, and peroxynitrite (Hopkins, 2016).  Excessive ROS production can lead 
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to significant cellular damage.  Doxorubicin is a quinone compound and has been 
proposed to undergo redox cycling, specifically in complex I of the mitochondrial 
electron transport chain.  During this process Dox may go through redox activation to a 
semiquinone intermediate (Dox-) which generates superoxide radical upon the one-
electron reduction of O2 (Dox- + O2 ® Dox + O2-) (Zhu et al., 2016).  Early research 
from Davies and Doroshow (1986) demonstrated that the quinone moiety of 
anthracyclines (doxorubicin) is reduced by one electron at complex I of the mitochondrial 
electron transport chain.  This results in the one-electron transfer to molecular oxygen to 
form superoxide anion, hydroxyl radical, and hydrogen peroxide (Davies & Doroshow, 
1986).  
Doxorubucin has a strong capacity to trigger apoptosis, autophagy, and 
morphology in skeletal muscle.  In mice Dox administration resulted in a trend towards a 
reduction in body weight in overall body weight and a significant increase in caspase-3, 
caspase-9 and calpain activity (Mitchell, Merkel, & Quadrilatero, 2015).  Equally, Dox 
administration has been shown to elevate Bax, caspase-3 activity, and apoptotic DNA 
fragmentation in aged mice skeletal muscle and C57BL/6 mice increasing apoptosis (Sin 
et al., 2016; Yu et al., 2014).  In cardiac tissue one of the mechanisms that leads to 
myocardial toxicity and heart failure following Dox administration is ROS-triggering of 
apoptosis (Childs, Phaneuf, Dirks, Phillips, & Leeuwenburgh, 2002; Singal et al., 2000; 
Takemura & Fujiwara, 2007).  
 Although not completely understood, Dox administration may produce ROS 
from a different mechanism.  It is well understood that a molecular target of Dox is 
topoisomerase IIa, which is found in proliferating cells and required for DNA replication 
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(Zhu et al., 2016).  However, this would not be relevant for cell that are not actively 
proliferating, such as skeletal muscle cells or cardiomyocytes.  Doxorubicin has also been 
shown to target topoisomerase IIb, which is present in the mitochondria of all quiescent 
cells (Vejpongsa & Yeh, 2014).  It has been suggested when topoisomerase IIb is target 
by Dox, resulting in DNA double strand breaks, defective mitochondrial biogenesis, and 
increased ROS accumulation (Zhang et al., 2016). Although not completely understood, 
the theory is, Dox inhibition of topoisomerase IIb may cause p53 activation via the 
mitochondrial DNA damage response, repression of PPARg, PGC1a, PGC1b, leading to 
mitochondrial dysfunction, increased electron leakage, superoxide formation, and 
subsequent further activation of p53 (Sahin & DePinho, 2012).  Regardless of the 
mechanism, whether direct ROS production through redox cycling, or increased 
topoisomerase IIb leading to ROS production, Dox administration leads to increased 
mitochondrial superoxide production, and damage to tissue.   
Creatine 
Creatine monohydrate (Cr) is one of the most widely used supplements ingested 
in an attempt to improve high intensity athletic performance. A large amount of research 
has been done on Cr supplementation in efforts to delineate its sport-specific effects. It 
has been hypothesized that Cr can act through a number of pathways and appears to be 
most effective in short-bout, high-intensity physical activities.  However, over the past 
decade Cr used for therapeutic and chemo preventive purposes has received increasing 
attention (Gualano et al., 2009).  Research has showed that Cr supplementation is 
beneficial in a large number of muscular, neurological, and cardiovascular diseases. 
Sharov et al. (1987) demonstrated that in the presence of exogenous phosphocreatine, a 
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rat heart that had been made ischemic for 35 minutes regained almost all heart function, 
phosphocreatine content, and 61% of adenosine triphosphate content, whereas only 33% 
recovery of heart function was observed in control.  Three days of subcutaneous creatine 
injections significantly reduced the rate of hypoxic seizures in 5-to-30-day-old rabbit 
pups (Holtzman et al., 1999).  Creatine supplement in the diets of Sprague Dawley rats 
was significantly protective against malonate and 3-nitropropionic acid induced 
neurotoxicity (Matthews et al., 1999).  In Duchenne muscular dystrophy, orally 
administered creatine monohydrate given to 9-year-old patients improved muscle 
performance (Felber et al., 2000).  Mazzini et al. (2001) demonstrated that creatine 
supplementation significantly increased maximal isometric power in 10 different muscle 
groups, in 28 patients with definite Amyotrophic Lateral Scelerosis.   Stout et al. (2001) 
supplemented a single patient with myasthenia gravis, 5 grams of Cr and 3 times per 
week resistance exercise for 15 weeks.  Stout et al. (2001) found that after creatine 
supplementation and training body weight, fat free mass, upper body strength, lower 
body strength and peak strength increased, without any negative effects on blood 
chemistry.   Creatine supplementation has been investigated in four transgenic mouse 
model of Huntington’s disease, resulting in a 19% improvement in survival, delayed 
onset of weight loss, slowed the development of motor symptoms, of brain atrophy, and 
of atrophy of striatal neurons, lessened the formation of intranuclear inclusions, and 
delayed the onset of diabetes (Wyss & Schulze, 2002).  Tarnopolsky et al. (2004) 
investigated oral Cr supplementation in seven patients with mitochondrial cytopathies 
and found that Cr supplementation increased high intensity anaerobic and aerobic 
performance. Tarnopolsky (2007) showed that Cr supplementation (5-10 g/day for 5 
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days) all indices of muscle strength in 102 patients with neuromuscular disease.  Lastly 
Bender et al. (2007) investigated the effect of oral Cr supplementation on aging in 162 
C57BI/6J and showed that supplementation increased median life span by 9%, improved 
performance on neurobehavioral tests, reduced ROS, lowered accumulation of “aging 
pigment” lipofuscin, upregulated genes implicated in neuronal growth, neuroprotection 
and learning.   
Creatine Metabolism 
Creatine, or N-aminoiminomethyl-N-methylglycine, is an endogenously formed 
amino acid that is taken up in diets containing fresh meat or fish.  Biosynthesis of 
creatine takes place in the liver and begins with the transfer of the amindino group of 
arginine (synthesized in the kidneys) to glycine to yield L-ornithine and guanidinoacetic 
acid, catalyzed by L-arginine:glycine amindinotransferase.  The enzyme S-adenosyl-L-
methionine:N-guanidinoacetate methyltransferase then methylates the amidino group on 
guanidinoacetic acid and forms creatine.  Worth noting and still largely accepted, is that 
creatine biosysnthesis first occurs in the kidneys with the formation of guanidinoacetate, 
which is then transported through the blood to the liver where guanidinoacetate is 
methylated to form creatine (Wyss & Kaddurah-Daouk, 2000).  Regardless of the route, 
creatine is then transported out of the liver, into the bloodstream, transported into the 
tissue via the sarcolemma bound creatine transporter (Murphy et al., 2001) and stored in 
the tissue (brain, brown adipose tissue, intestine, seminal vesicles fluid, endothelial cells, 
and marcrophages) with the about 95% stored in skeletal muscle (Cooper, Naclerio, 
Allgrove, & Jimenez, 2012).  Once in skeletal muscle, Cr undergoes what is referred to as 
the phosphocreatine (PCr) ‘shuttle’ system.  The PCr shuttle system occurs in the 
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mitochondria, where a high-energy phosphate is transferred from ATP formed in 
oxidative phosphorylation, to the guanidine group on Cr, via the enzyme creatine kinase 
mitochondria (CKmito).  Phosphocreatine then diffuses out of the mitochondria into the 
cytoplasm, where the creatine kinase cytosolic isoform catalyzes the reversible transfer of 
the N-phosphoryl group from PCr to ADP to regenerate ATP.  The ATP is then localized 
to areas of need, and the Cr returns to the interior of the mitochondria (Wyss & 
Kaddurah-Daouk, 2000).  A constant fraction of the body creatine (1.1%) and PCr (2.6%) 
are spontaneously and nonenzymatically converted to creatinine, with this reaction being 
both pH and temperature dependent (Wyss & Kaddurah-Daouk, 2000).  Creatinine will 
then diffuse out of the cell, into the blood, and is excreted by the kidneys into the urine.  
The converted creatinine then has to be replaced by Cr from the diet or from de novo 
biosynthesis (Walker, 1979).   
Creatine and Apoptosis 
As described in the section above, apoptosis is a morphologically distinct and 
important mode of ‘programmed’ cell death that occurs in mammalian cells. As stated 
earlier, creatine supplementation can benefit a large number of muscular, neurological, 
and cardiovascular diseases.  One such mechanism may be creatine’s ability to modulate 
apoptosis.    
Rahimi, Mirzaei, Rahmani-Nia, and Salehi (2015) examined the effects of 
creatine monohydrate supplementation on apoptotic markers and found that creatine 
monohydrate supplementation prevented exercise induced apoptosis, as measured by 
decreases in p53 concentration.  It is well known that p53 plays a significant role in 
regulating apoptosis by affecting the expression of apoptotic peptidase activating factor-1 
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and by altering mitochondrial membrane potential (Haldar, Negrini, Monne, Sabbioni, & 
Croce, 1994; Moll & Zaika, 2001).  Rahimi (2011) suggested that the increase in 
oxidative stress with aerobic exercise signal p53, which in turn triggered the p53 
dependent apoptotic pathway to preserve genomic intensity and cellular homeostasis.  
Although not directly measured, Rahimi et al. (2015) suggest that Cr may act as an 
antioxidant, scavenging ROS.  This then reduces the ROS-induced signaling of p53, 
which was one of the findings of the study, reduced serum p53 concentration with Cr 
supplementation.  Sheikholeslami-Vatani and Faraji (2018) equally found that creatine 
supplementation reduced apoptotic markers with exercise, reducing caspases (-3 and -9), 
p53, and Bax when compared to placebo.   
Sheikholeslami-Vatani and Faraji (2018) suggest that although not directly 
measured, the reduction in the apoptotic markers may have been due to the ability for Cr 
supplementation to reduce ROS production which reduced the signaling of the apoptotic 
caspases (-3 and -9) and p53.  Lastly, in exercise-induced apoptosis, Cr supplementation 
reduced lipid peroxidation and glutathione peroxidase activity, and attenuated oxidative 
DNA damage, with the suggested mechanisms being the potential ROS scavenging 
capabilities (Basta, Skarpan’ska-Steinborn, & Pilaczyn’ska-Szczes’niak, 2006; Mirzaei, 
Rahmani-Nia, Salehi, & Rahimi, 2013; Rahimi, 2011).  Although not completed in 
skeletal muscle, Zhu et al. (2004) showed that in focal cerebral ischemia, Cr 
supplementation either directly or indirectly inhibited cytochrome c release and 
downstream caspase-3 activation. Equally, Cr supplementation has been shown to reduce 
caspase-3/7 activation in HL-1 cardiomyocytes (Santacruz et al., 2015). In summary, Cr 
supplementation can reduce markers of apoptosis in a variety of conditions.  Although the 
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mechanisms are not elucidated, it is postulate that Cr acts an antioxidant, scavenging free 
radicals, and reducing their quantity which ultimately reduces apoptosis.   
Creatine as an Antioxidant 
 Creatine is the most widely used supplement advocated as an ergogenic aid 
(Kraemer & Volek, 1999).  The literature claims creatine supplementation increases lean 
body mass, skeletal muscle strength, muscle power, and endurance (Dangott, Schultz, & 
Mozdziak, 2000; Demant & Rhodes, 1999; Ingwall, 1976; Jones, Atter, & Georg, 1999; 
Reid, Stokic, Koch, Khawli, & Leis, 1994).  Recently, it has been suggested that creatine 
could possess an antioxidant effect.  
As mentioned, creatine is a downstream product of the amino acids glycine and 
arginine.  Arginine is a substrate in the formation of the free radical nitric oxide which is 
involved in modulating metabolism, contractility of smooth and skeletal muscle, and 
skeletal muscle glucose uptake (Lawler & Powers, 1998; Reid, 2001). It has been 
demonstrated that amino acids such as histidine, methionine, and cysteine are susceptible 
to free radical oxidation, and it is possible, that due to the amino acid makeup of creatine, 
it may be susceptible to free radical oxidation as well. In fact, Vergnani et al. (2000) 
showed a protective role of arginine against oxidative stress in endothelial cells.  Equally, 
Wu and Meininger (2000), indicated that arginine may be able to quench free radicals 
such as superoxide anions (O2-).  Matthews et al. (1998) first proposed that creatine 
supplementation provides direct or indirect antioxidant protection against metabolic 
damage in a Huntington’s disease mouse model.  Lawler, Barnes, Wu, Song, and 
Demaree (2002) showed that creatine has the ability to act as a direct antioxidant, capable 
of removing 3 charged free radical and ROS, superoxide anions (O2-), peroxynitrite 
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(OONO-), and 2,2’-azino-bis (3-ethylbenzothiaxoline-6-sulfonic acid) (ABTS+). 
Important to note Lawler et al. (2002) observed that it was creatine, not creatine 
phosphate, that was capable of scavenging charged radicals and the study was conducted 
in an acellular setting.   
Sestili et al. (2006) expounded on Lawler’s findings and investigated the 
antioxidant effects of creatine on three mammalian cell lines and found Cr preloading to 
be mildly but significantly cytoprotective in a dose related manner.  In a follow up study, 
Sestili et al. (2007) using HPLC, in an attempt to understand whether the cytoprotective 
effects of Cr depend on antioxidant or an energy-related mechanism, found that tissues 
accumulated free Cr at different levels, and that protection occurred only when free Cr 
levels reached a certain threshold.  The aforementioned study identified that the cells 
(U937, HUVEC, and C2C12) pretreated with Cr and treated with H2O2 formed an 
oxidation product with a molecular weight of 136amu and 150amu, with these structures 
still needing to be better defined by means of infrared spectroscopy and mass-mass 
spectrometry (Sestili et al., 2007).  In a separate study, Sestili et al. (2009) showed that Cr 
pre-treatment significantly protected mitochondrial DNA from oxidative damage, with 
respect to H2O2-treated, Cr unsupplemented samples, and again, that the protective 
effects were Cr dose dependent.  
Doxorubicin has been shown to act as both an alkylating and an oxidizing agent, 
damaging RNA (Fimognari, Sestili, Lenzi, Cantelli-Forti, & Hrelia, 2009).  Cr 
supplementation was able to reduce the RNA damage in Jurkat T-leukemia cells 
incubated in H2O2 and Dox (Fimognari et al., 2009).  Lastly, Cr supplementation 
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significantly and dose-dependently attenuated the cytotoxic impact of H2O2 to 
differentiating C2C12 myoblasts (Sestili et al., 2009).   
In closing, it is well established that Cr supplementation can improve athletic 
performance (Earnest, Snell, Rodriguez, Almada, & Mitchell, 1995). More recently, 
research has demonstrated that Cr supplementation may beneficial in a large number of 
muscular, neurological, and cardiovascular diseases (Bender et al., 2007; Felber et al., 
2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al., 
2001; Neubauer et al., 1999; Sharov et al., 1987;  Stout et al., 2001; Tarnopolsky et al., 
2004; Tarnopolsky, 2007; Vorgerd et al., 2000; Wyss & Schulze, 2002).   Free Cr, not Cr 
bound to a phosphate, can reduce apoptosis in various types Dox treated cells, possible 
through its proposed antioxidant capacity.  Overall, Cr supplementation is well tolerated 
in humans, with the most common side effect being diarrhea and bloating.   Equally, Cr 
supplementation is easy to ingest, whether mixed in a liquid or taken as a pill and can be 
taken with or without food.  In light of the aforementioned, Cr supplementation may be 
valuable nutraceutical treatment to reduce Dox-induced muscle fatigue that affects so 



















 The current study examined the effects of a nutritional intervention, using two 
types of creatine feeding interventions: 2% creatine feeding for four weeks (C1) and 4% 
creatine feeding for one week followed by 2% creatine feeding for three more weeks 
(C2).  Equally, the study examined a drug effect, with rats receiving either a 15 mg/kg 
injection of Dox or an equivalent sterile saline injection (Sal).  Lastly, animals were 
sacrificed either 1-day post injection or 3-days post injection. Western blotting technique 
measured the apoptotic markers, cleaved poly ADP ribose polymerase (PARP), cleaved 
caspase-3, and caspase-3 in the fast, type II extensor digitorum longus (EDL), the slow, 
type I soleus (SOL) and the diaphragm (DIA).  Upon sacrifice, tissues were harvested, 
flash frozen in liquid nitrogen, and stored at -80°C for biochemical analysis.   
Subjects 
 All protocols used for the study were approved by the University of Northern 
Colorado Institutional Animal Care and Use Committee and followed the Animal 
Welfare Act guidelines. Male Sprague Dawley rats (120 total animals; 60 animals x 1 day 
and 60 animals x 3 day) were purchased from Envigo and housed at the University of 
Northern Colorado Research Facility.  All animals were housed individually in a 
temperature-controlled facility with a 12-hour light/12-hour dark cycle.  Animals were 
provided their nutritional intervention and water ad libitum.   
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 At 10 weeks of age, the animals were assigned to one of two, four-week creatine 
feeding interventions or control feeding referred to below (See Table 1.).  The first 
feeding protocol (creatine feeding protocol 1 or C1) attempted to duplicate human dosing 
of creatine, which is typically, 10 grams per day.  Creatine feeding protocol 1 (C1) 
consisted of a rodent chow supplemented with 2% creatine and was feed ad libitum to the 
rodents for 4 weeks.  The second feeding protocol (creatine feeding protocol 2 or C2) 
attempted to duplicate the human equivalent of a loading phase, which is taking 5 grams 
of Cr, 4 times per day, for 7 days, then to a maintenance dose of 10 grams a day for the 
duration of the supplement period.  Creatine feeding protocol 2 (C2) consisted of a rodent 
chow supplemented with 4% creatine for one week, followed by rodent chow 
supplemented with 2% creatine for three weeks (creatine feeding protocol 2, C2).  
Animals assigned to the control group were fed standard rodent chow (Teklad Global) 
which is 16.4% protein, 4% fat, 48.5% carbohydrate, and 3.3% fiber, made 
predominantly from ground wheat, ground corn, and wheat middlings, for four weeks. 
At the end of four-week nutritional intervention, the animals were randomly 
assigned to receive either an intraperitoneal bolus 15 mg/kg Dox injection or an 
equivalent sterile saline injection (Sal).  The final volume of the Doxorubicin injection 
was calculated by first multiplying the animals body mass by 15mg/kg, then dividing by 
the 2mg/ml Doxorubicin concentration.  Following injections, the animals were assigned 
to be sacrificed either 1-day post injection or 3-days post injection, and continued diet.   
Animals were anesthetized with sodium pentobarbital (50 mg/kg).  After the 
rodent was completely anesthetized (i.e., no response with a tail pinch) the left soleus 
(SOL), left extensor digitorum longus (EDL), and diaphragm (DIA) were removed, 
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Experimental design for treatments. 
Group 
 
Diet  Drug  Sacrifice Time 
Con-Sal 4 wks Con Diet Sal 1 day (n=10), 3 day (n=10) 
Con-Dox 4 wks Con Diet Dox 1 day (n=10), 3 day (n=10) 
C1-Sal 4 wks 2% Cr Diet Sal 1 day (n=10), 3 day (n=10) 
C1-Dox 4 wks 2% Cr Diet Dox 1 day (n=10), 3 day (n=10) 
C2-Sal 1 wk 4% Cr Diet - 3 wks 2% Cr Diet Sal 1 day (n=10), 3 day (n=10) 
C2-Dox 1 wk 4% Cr Diet - wks 2% Cr Diet Dox 1 day (n=10), 3 day (n=10) 
Note. Con-Sal = control saline, 1 day n=10, 3 day n=10; Con-Dox = control doxorubicin, 1 day n=10, 3 day n=10; C1-Sal = creatine 1 
saline, 1 day n=10, 3 day n=10; C1-Dox, creatine 1 doxorubicin, 1 day n=10, 3 day n=10; C2-Sal, creatine 2 saline, 1 day n=10, 3 day 










 The SOL, EDL and DIA were homogenized in a cocktail of 
radioimmunoprecipitation (RIPA) buffer at a 1:10 weight:volume ratio and 10 µl protease 
enzyme inhibitor (Santa Cruz Biotechnology).  The tissue samples (between 0.7-1.0 
grams) were manually homogenized using a Cole-Parmer PTFE tissue grinder (Cole-
Parmer: Vernon Hills, IL), sonicated using 10 x 1 second bursts (Fischer Scientific, Sonic 
Dismembrator, Model 100), and then transferred to a 2 ml eppendorf tube.  The 
homogenate was centrifuged for 10 minutes at 10,000 g, the pellet discarded, and the 
supernatant transferred to a new 2 ml Eppendorf.  A Bradford Assay was performed to 
assess total protein concentration using a Genesys 20 photo spectrometer 
(ThermoSpectronic: Rochester, NY) at 595 nanometers. Radioimmunoprecipitation assay 
buffer (RIPA) and Laemmli Sample Buffer (Sigma-Aldrich) was pipetted into each 
sample to standardize the concentration of each sample.   
Western Blotting  
Western blot analysis was conducted on the, SOL, EDL, and DIA for the presence 
of cleaved PARP (24 kilodalton), caspase-3 (32 kilodalton), and cleaved caspase-3 (17 
kilodalton), and used the 35.8 kilodalton, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as the loading control.  Prepared samples were boiled in water for 2 minutes, 
chilled for 5 minutes on ice, with 15 µl loaded onto 4 - 20% Tris-Glycine (Invitrogen) 
precast gels, along with 10µl SeeBlue protein standard (Thermo Fisher Scientific) and 10 
µl of MagicMark XP western protein standard (Thermo Fisher Scientific).  Gels were run 
at a constant 125V at 4 mA in an Xcell II blot module (ThermoFisher Scientific) until 
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tracking dye reaches bottom of the gel.  Once the protein migration was complete, the 
proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane at 25 volts 
and100 mA for 90 minutes.  Membranes were blocked using 10 ml WesternBreeze TM 
Superblocker Solution (ThermoFisher Scientific) for 30 minutes, washed twice in water 
for 5 minutes and then incubated overnight at room temperature in 10 mL of primary 
antibody solution.  Membranes were then washed four times in 10 mL of WesternBreeze 
Wash Solution (ThermoFisher Scientific) and incubated for 1 hour in the species-specific 
secondary antibody conjugated with horseradish peroxidase (HRP).  Membranes were 
then washed 4 more times with WesternBreeze Wash Solution and prepared for protein 
band detection.   
Protein band detection involved incubating the membranes in 
Enhancedchemiluminescence (ThermoFisher Scientific, ECL) solution containing 
peroxide buffer and luminol substrate, mixed in a 2 mL microcentrifuge tube 
(concentration 1:1) and poured onto the center of the opened C-Digit imager (Li-Cor: 
Lincoln, NE).  Membranes were placed on top of the substrate face down for 5 minutes.  
A cellophane sheet was then placed on top of the membrane, the lid closed, and the C-
Digit imager captured the image.  Optical density of the protein bands was quantified 
using Image J (NIH: Bethesda, MD).  The ratio of cleaved PARP was quantified and this 
value was divided by the optical density of GAPDH for the final optical density for 





Characteristics of antibodies used for Western blotting. 
Antibody name Dilution ratio Species specificity Source Supplier Catalog No. 
GAPDH  1:1000 Rabbit Mouse mAB Santa Cruz Bio Sc-32233 
Caspase-3  1:200 Human Mouse mAB Santa Cruz Bio Sc-5603 
PARP-1 1:200 Human Mouse mAB Santa Cruz Bio Sc-8007 
M-IgGk BP-HRP 1:1000 Anti-mouse  Santa Cruz Bio Sc-516102 
Note. GAPDH = glyceraldehyde-3-phosphate dehydrogenase, PARP-1 = poly (ADP-ribose) polymerase-1, M-IgGk BP-HRP = mouse 




 Creatine and phosphocreatine levels were analyzed in the SOL, EDL, and DIA at 
both the 1-day and 3-days post injection time points using the commercially available 
creatine assay kit (Abcam).  Skeletal muscle samples (0.7-1.0 g) were homogenized in 
radioimmunoprecipitation assay buffer (RIPA buffer), centrifuged for 10 minutes at 
10,000 x g, then the supernatant transferred to a clean tube and the pellet discarded.  The 
reagents were then prepared using the materials supplied by the Creatine Assay Kit. Prior 
to beginning the equipment was equilibrated and the reagents brought to room 
temperature and all standards, controls, and samples duplicate.  The creatine standard 
wells were filled with 25 µl of the creatine standard, and 25 µl of the reaction mix.  The 
sample wells were filled with 8 µl of tissue supernatant, 17 µl of creatine assay buffer, 
and 25 µl of reaction mix.  The wells were mixed for 2 minutes and incubated in the dark 
at 37°C for 60 minutes. Measurement of the wells were done on a microplate reader at 
570 nm and expressed as the molar concentration of creatine per whole tissue. 
Statistical Analysis 
Data was presented as means ± standard error (mean±SEM).  A two-way (diet x 
drug) analysis of variance (ANOVA) was used at each time point to determine main diet 
effect, drug effect, diet x drug, of the dependent variables (apoptotic markers: cleaved 
PARP, caspase-3, cleaved caspase-3, and creatine concentration).  When ANOVA 
significant main effects and/or interaction were observed, and a Tukey’s post hoc testing 












The purpose of this study was to determine the effects of two separate creatine 
feeding, and acute Dox administration on apoptosis in skeletal muscle.  This study 
investigated the expression of cleaved PARP, caspase-3, and cleaved caspase-3 at two 
separate time points following a bolus Dox injection. Equally, the concentration of total 
Cr was measured in EDL, SOL, and DIA. This chapter presents the findings of the study.   
General Observations 
 Table 3 presents the animal characteristics at the time of injection and at the 1-day 
sacrifice time point.  At the time of injection, there were no main effects observed in 
body mass between groups, p>0.05.  At the time of sacrifice, a drug effect was observed 
with Dox animals exhibiting significantly lower body mass, F (1, 54) = 6.91, p<0.05.  In 
the EDL, there was a significant drug effect, with Dox animals having significantly lower 
EDL mass, F (1, 50) = 4.24, p<0.05.  In the SOL there was a significant drug effect, F (1, 
54) = 5.759 and diet x drug interaction, F (2, 54) = 5.12, p<0.05, with Dox animals 
having significantly lower SOL mass.  Post hoc tests revealed SOL mass to be 
significantly lower in the Con-Dox than Con-Sal. In the DIA, no significant main effects 




1-day animal characteristics. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Injection Mass (g) 390 ± 7 394 ± 10 400 ± 5 395 ± 9 387 ± 9 380 ± 14 
Sacrifice Mass (g) ‡ 388 ± 7 374 ± 9 397 ± 5 377 ± 9 386 ± 9 361 ± 13 
EDL Mass (mg) ‡ 172 ± 12 143 ± 5 166 ± 8 140 ± 18 154 ± 12 148 ± 6 
SOL Mass (mg) ‡+ 148 ± 5 134 ± 4 * 147 ± 4 147 ± 3 144 ± 5 143 ± 6 
DIA Mass (mg) 261 ± 29 261 ± 21 271 ± 18 249 ± 24 232 ± 21 266 ± 14 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=10; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
‡ = signficant drug effect (p<0.05) 
+ = significant interaction (p<0.05) 














Expression of the apoptic proteins, cleaved PARP, caspase 3, and cleaved caspase 
3, were measured in the SOL, EDL, and DIA homogenates at the 1 and 3 day time points 
to evaluate the influence of creatine monohydrate and Dox on their expression.  Forty six 
µg of protein from the 1 day and 3 day, SOL, EDL, and DIA homogenates were added to 
4-20% Tris-glycine precast gels and run through SDS-PAGE.  Cleaved PARP, caspase-3, 
and cleaved caspase-3 levels were assessed by enhanced chemiluminescence and are 
expressed relative to GAPDH as a loading control.  No signficiant GAPDH main effects 
or interactions (p>0.05) were observed, suggesting that the drug and diet treatments did 














One-day extensor digitorum longus apoptotic protein levels.  In the EDL, 
cleaved PARP levels were higher with the administration of Dox, F (1, 52) = 28.12, 
p<0.05 (Figure 4A). Post hoc tests revealed that Con-Dox, C1-Dox, C2-Sal, and C2-Dox 
expressed significantly higher levels of cleaved PARP than C1-Sal. Post hoc tests also 
revealed that C2-Dox expressed significantly higher levels of cleaved PARP than Con-
Sal (Figure 4A). A 2-way ANOVA revealed a significant diet effect, with creatine groups 
exhibiting lower levels of caspase-3, F (2, 53) = 4.142, p<0.05 (Figure 4B). No 














Figure 4. 1-day EDL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con-Sal = 
control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, 
n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox 
= creatine 2 doxorubicin, n=10; Values are mean ± SEM. 
(A) significant drug and diet effect (p<0.05) 
(B) significant diet effect (p<0.05) 
* = significantly different from C1-Sal  




One-day soleus apoptotic protein levels.  For cleaved PARP, a significant drug 
effect was observed, with Dox groups exhibiting higher levels of cleaved PARP, F (1, 
50) = 6.30,  p<0.05 (Figure 5A).  A diet effect was observed, with Cr groups expressing 
higher levels of cleaved PARP, F (2, 20) = 5.41, p<0.05. No significant interaction was 
detected. Post hoc tests also showed that Con-Sal, C1-Sal, C1-Dox, and C2-Sal expressed 
significantly lower levels of cleaved PARP than C2-Dox (Figure 5A).  No significant 
main effects were observed and no interaction was detected for caspase-3 (Figure 5B). 
Cleaved caspase-3 levels were lower with diet, F (2, 52) = 3.43, p<0.05 (Figure 5C), and 






Figure 5. 1-day SOL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
SOL = soleus, kDa = kilodalton, OD = optical density, Con-Sal = control saline, n=10; 
Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = 
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 
doxorubicin, n=10. Values are mean ± SEM. 
(A) significant drug ffect (p<0.05) 
(C) significant diet effect (p<0.05) 




One-day diaphragm apoptotic protein levels.  In the DIA, a significant diet 
effect was observed, with Cr groups exhibiting lower levels of cleaved caspase 3, F (2, 
52) = 5.01,  p<0.05 (Figure 6C).  No main effects or interaction observed for cleaved 






Figure 6. 1-day DIA apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con-Sal = control saline, 
n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = 
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 
doxorubicin, n=10. Values are mean ± SEM. 
(C) significant diet effect (p<0.05) 
	 50 
	
Table 4 presents the animal characteristics at the 3 day sacrifice time point.  At the time 
of injection there were no significant difference in body mass between groups, p>0.05.  
At the time of sacrifice, a main effect was observed in animal body mass, p<0.05. A drug 
effect was observed with Dox animals exhibiting significantly lower body mass, F (1, 54) 
= 11.34, p<0.05.   
There was a main effect in EDL, SOL, and DIA mass, p<0.05.  In the EDL, there 
was a drug effect, with Dox animals exhibiting significantly lower tissue mass, F (1, 51) 
= 11.72, p<0.05.  Post hoc testing revealed EDL mass to be significantly lower in the C1-
Dox than Con-Sal.  In the SOL, there was a drug effect, with Dox animals exhibiting 
significantly lower tissue mass, F (1, 51) = 4.39, p<0.05.  Lastly, in the DIA there was a 
significant drug effect, with Dox animals exhibiting significantly higher tissue mass, F 





3-day animal characteristics. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Injection Mass (g) 386 ± 13 381 ± 4 373 ± 5 387 ± 10 375 ± 6 392 ± 6 
Sacrifice Mass (g) ‡ 387 ± 13 351 ± 9  374 ± 5 353 ± 13  378 ± 6 352 ± 8  
EDL Mass (mg) ‡ 160 ± 7 142 ± 4  153 ± 7 127 ± 8 *  154 ± 6 134 ± 11  
SOL Mass (mg) ‡ 158 ± 9 134 ± 3  137 ± 8 137 ± 5  153 ± 7 141 ± 3  
DIA Mass (mg) ‡ 229 ± 21 285 ± 43  243 ± 32 299 ± 23  245 ± 16 277 ± 14  
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
Significant drug effect in Sacrifice Mass (p<0.05). 
‡ = signficant drug effect (p<0.05) 




Three-day extensor digitorum longus apoptotic protein levels.  No main 
effects or interaction was observed for cleaved PARP and caspase-3 (Figures 7A and 7B).  
A 2-way ANOVA revealed a significant diet effect, with Cr groups exhibiting higher 
levels of cleaved capase-3, F (2, 49) = 17.96, p<0.05 (Figure 7C). Cleaved caspase-3 
levels were higher in the Dox groups, F (1, 49) = 0.1880, p<0.05 (Figure 7C).  Lastly, an 
interaction was observed, with the highest cleaved caspase-3 levels observed in the C1-
Dox group, F (2, 49) = 7.230, p<0.05 (Figure 7C).  Post hoc tests revealed that C1-Sal, 
C1-Dox, and C2-Sal produced significantly higher levels of cleaved caspase-3 than Con-
Sal.  Equally, post hoc tests exposed C1-Dox and C2-Sal expressed significantly higher 
levels of cleaved caspase-3 than Con-Dox.  Lastly, post hoc tests showed C2-Dox 

















Figure 7. 3-day EDL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con-Sal = 
control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, 
n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox 
= creatine 2 doxorubicin, n=10. Values are mean ± SEM. 
(C) significant drug and diet effect (p<0.05) 
(C) significant interaction (p<0.05) 
* = significantly different from Con-Sal  
† = significantly different from Con-Dox 




Three-day soleus apoptotic protein levels.  No main effects or interaction was 
observed for cleaved PARP (Figure 8A).  A 2-way ANOVA revealed a significant drug 
effect, with Dox groups exhibiting lower levels of capase-3, F (1, 52) = 4.776, p<0.05 














Figure 8. 3-day SOL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
(A) cleaved PARP, (B) caspase-3, (C) cleaved caspase-3; SOL = soleus, kDa = 
kilodalton, OD = optical density, Con-Sal = control saline, n=10; Con-Dox = control 
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, 
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values 
are mean ± SEM. 









Three-day diaphragm apoptotic protein levels.  A 2-way ANOVA revealed a 
significant drug effect, with Dox groups exhibiting lower levels of cleaved PARP F (1, 
54) = 11.24, p<0.05 (Figure 9A).  Post hoc tests revealed that Con-Dox expressed 
significantly lower levels of cleaved PARP than Con-Sal (Figure 9A).  No significant 
main effects or interaction was detected for caspase-3 (Figure 9B) and cleaved caspase-3 


















Figure 9. 3-day DIA apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C) 
cleaved caspase-3. 
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con-Sal = control saline, 
n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = 
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 
doxorubicin, n=10. Values are mean ± SEM. 
(A) significant drug effect (p<0.05) 









Creatine Assay  
Creatine levels were  measured in the SOL, EDL, and DIA at the 1 and 3-day time 
points to evaluate the effects of Cr feeding and Dox administration on the concentration 
of creatine monohydrate in skeletal muscle.  Eight µL of the supernatant from the 1-day 
and 3-day, SOL, EDL, and DIA homogenates were added to 17 uL of creatine assay 
buffer, in a 96 well plate.  Twenty-five µL of the creatine reaction mix was then added to 
each well, and was incubated at 37°C for 1 hour.  The plates were then measured at 570 
nm using a microplate reader.  Results were expressed as molar (M) creatine 
concentration per whole skeletal muscle (g).   
One-day creatine concentration.  In the 1-day EDL, a 2-way ANOVA revealed 
no significant effects or interaction (Figure 10).  In the SOL, a drug effect was observed, 
with Dox groups displaying lower creatine concentrations, F (1, 50) = 8.005, p<0.05 






Figure 10. 1-day EDL creatine concentration. 
EDL = extensor digitorum longus; Con-Sal = control saline, n=10; Con-Dox = control 
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, 
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values 
are mean ± SEM. 







































Figure 11. 1-day SOL creatine concentration. 
SOL = soleus; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; 
C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = 
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM. 















































Figure 12. 1-day DIA creatine concentration. 
DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, 
n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = 
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM. 








































Three-day creatine concentration.  In the EDL, a 2-way ANOVA revealed a 
significant diet effect F (2, 53) = 4.668, p<0.05; drug effect F (1, 53) = 29.71, p<0.05 
(Figure 13).   Post hoc test revealed that Con-Dox, C1-Sal, C1-Dox, and C2-Dox had 
significantly lower Cr concentration than Con-Sal (Figure 13). Additionally, post hoc test 
revealed C2-Dox had significantly lower Cr concentration than C2-Sal (Figure 13). No 
significant main effects were observed and no interaction was detected in the SOL 
















Figure 13. 3-day EDL creatine concentration. 
EDL = extensor digitorum longus; Con-Sal = control saline, n=10; Con-Dox = control 
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, 
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values 
are mean ± SEM. 
Significant diet effect (p<0.05) 
Significant drug effect (p<0.05) 
* = significantly different than Con-Sal (p<0.05) 














































Figure 14. 3-day SOL creatine concentration. 
SOL = soleus; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; 
C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = 
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM. 


















































Figure 15. 3-day DIA creatine concentration. 
DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, 
n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = 
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM. 
















































At the time of injection, at both the 1 and 3-day time points, main effects were not 
observed in animal body mass.  There was a significant drug effect in the sacrifice body 
mass at both the 1 and 3-day time points, with Dox treated animals displaying lower body 
masses.  In both the 1 and 3-day EDL and SOL, there was a significant drug effect in 
tissue mass with the Dox groups having lower tissue mass.  Equally, the 3-day DIA 
experienced a significant decrease in tissue mass.  No mass differences were seen in the 
1-day DIA.  
Cleaved PARP levels were increased with Dox and Cr in both the 1-day EDL and 
SOL and decreased in the 3-day DIA.  Cleaved PARP levels were not significantly 
different in the 1-day DIA or 3-day EDL or SOL.  Caspase-3 levels were lower in the 1-
day EDL Cr groups and were higher in the 3-day SOL Dox gropus.  There was not a 
significant change in caspase-3 levels in the 1 or 3-day DIA, nor the 1-day SOL and 3-
day EDL. Cleaved caspase-3 levels were lower in both the 1-day SOL and DIA Cr 
groups, but not in the 1-day EDL.  Cleaved caspase-3 levels were lower in both Cr, Dox 
groups and showed an interaction in the 3-day EDL, with no main effects observed in the 
3-day SOL or DIA.    
Total Cr concentration was lower in the 1-day SOL and 3-day EDL with Dox 
administration.  Total Cr concentration was overall lower in the 3-day EDL Cr groups.  
There were no main effects or interaction observed in the 1-day EDL and DIA;  3-day 














DISCUSSION AND CONCLUSIONS 
 
 This is the first study to assess two types of Cr diets and in vivo Dox treatment, at 
two separate time points on apoptosis in skeletal muscle.  It was hypothesized that Dox 
would increase levels of the apoptotic proteins cleaved PARP, cleaved caspase-3, and 
decrease levels of caspase-3 at both time points in all tissues and that Cr feeding would 
attenuate these effects.  The major findings are that 1) Dox did not increase cleaved 
PARP and cleaved caspase-3 levels in all muscles analyzed and only affected cleaved 
caspase-3 levels in one condition, 2) Cr feeding did not attenuate the effects of Dox on 
these apoptotic proteins.   
Doxorubicin and Creatine’s Effect 
on Animal Characteristics 
 
  Dox animals had significantly lower sacrifice body masses at both time points.  
Equally, when the 1 and 3-day EDL and SOL were excised and weighed, the Dox 
animals had significantly lower tissue mass when compared to non-Dox treated groups.  
This was the same for the 3-day DIA, but not the 1-day DIA.  These findings are 
supported by previous research demonstrating that Dox injections decrease muscle mass 
in mice (Doroshow et al., 1985).  Creatine feeding had no effect on sacrifice body or 
skeletal muscle mass, which indicates Cr was not effective at reducing skeletal muscle 





Doxorubicin’s Effect on Apoptotic Proteins 
Dox-induced oxidative stress is one of the most pronounced mechanisms by 
which toxicity and eventual apoptosis is triggered in cells (Wang et al., 2004).  The 
development of oxidative stress with Dox treatment is propelled by two mechanisms, 
increased levels of ROS following Dox treatment and the downregulation of antioxidant 
enzymes following Dox administration.  The first, increased ROS levels, may result from 
different mechanisms, 1) decreased cellular antioxidant defenses, 2) disruption of the 
mitochondrial electron transport chain with subsequent electron leakage, and 3) the 
ability of Dox to undergo redox cycling and produce ROS (Zhao et al., 2010).  
Doxorubicin redox cycling leading to ROS production is the most widely recognized 
mechanism by which oxidative stress increases with Dox administration.   
Reactive oxygen species, particularly H2O2, generated by Dox administration, 
causes formation of a pore in the mitochondrial membrane, activation of caspase 9, and 
ultimately the formation of executioner caspase-3, 6, and 7 (Kluck et al., 1997; Li et al., 
1997; Nie et al., 2008; Pan et al., 1998; Reed, 1997; Zou et al., 1997).  Once caspase-3 is 
activated, downstream death substrates are cleaved, including poly (ADP-ribose) 
polymerase (PARP) (Janicke et al., 1998).   
In the current study, rats were administered a 15 mg/kg bolus interaperitoneal 
injection of Dox and sacrificed 1-day or 3-day post-injection.  Doxorubicin 
administration only affected cleaved caspase-3 levels in 3-day EDL, caspase-3 levels in 
the 3-day SOL, and cleaved PARP in the 1-day EDL and SOL, and 3-day DIA.  
Doxorubicin administration had no other significant effect on these particular apoptotic 
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proteins in any other condition.  These results agree with the original hypothesis that Dox 
administration will increase levels of cleaved PARP, cleaved caspase-3, and decrease 
levels of caspase-3. The literature, clearly demonstrates that Dox administration increases 
caspase-3 activation in cell culture, rodent cardiomyocytes and roden tcardiac tissue, 
resulting in activation of cleaved caspase-3 and eventually cleaved PARP (Asakura et al., 
1999; Ueno et al., 2006).  Doxorubicin also had a greater effect on 3-day apoptotic 
proteins, than 1-day apoptotic proteins.  Research has demonstrated that Dox 
accumulation and effects differ depending on the tissue and on the length of time spent in 
the tissue (Chenard, Fabris, & MacLean, 2012).  Chenard et al. (2012) found Dox 
accumulation is time dependent, which could explain why Dox administraiton had the 
greatest impact on apoptotic protein levels in the 3-day tissues.  Equally, Hayward et al. 
(2013), examined Dox accumulation in cardiac and skeletal muslce tissue and found that 
Dox accumulation is highest in cardiac tissue and accumulation differs in the EDL and 
SOL.  Hayward et al. (2013) postulated that the accumulation differed due to Dox’s 
affinity to accumulate in the mitochondria, and tissues with higher mitochondria content 
have higher levels of Dox accumulation.  Interestingly, Dox effects on cleaved PARP did 
not follow this rationale of a greater Dox effect on 3-day tissue as compared to 1-day 
tissue. Cleaved PARP levels increased in 1-day EDL and SOL, and not on 3-day EDL or 
SOL.  Even more confusing is the decrease in cleaved PARP levels observed in the 3-day 
DIA. Additionally, previous research has demonstrated that cleaved caspase-3 is a direct 
activator of cleaved PARP, cleaving PARP and activating it (Slee et al., 2001).  It would 
follow then, that if Dox administration increased cleaved PARP levels, a subsequent 
increase in cleaved caspase-3 and decrease in procaspase-3 would follow in that tissue.  
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This was not the case, there was not an increase in cleaved PARP and cleaved caspase-3 
levels and a subsequent decrease in caspase-3, in any condition.  
One explanation for the seemingly uncharacteristic response of cleaved PARP to 
Dox administration is the PARP-1 gene is expressed constitutively.  Its activation cannot 
be surmised from increased protein expression, but rather by measuring the consumption 
of the substrates used in its catalytic reaction (Shah et al., 2011).  According to Shah et al. 
(2011), to accurately measure PARP-1 activation in vivo, assessment of the formation of 
pADPr, depletion of the substrate NAD+, or formation of protons resulting in the rapid 
and reversible intracellular acidification, is the the most accurate and sensitive methods.  
Presently, it is possible, that the results for cleaved PARP do not agree with the research, 
not because Dox administration had no effect, but rather because the laboratory technique 
used (Western blot) is not sensitive enough to accurately detect the activation of PARP-1.   
In summary, if research by Shah et al. (2011) is correct, and in the current study 
the laboratory technique used to measure cleaved PARP was not sensitive enough and we 
interpret the results with caution, then what we presently observe is Dox administration 
only affected apoptotic proteins in 3-day tissue, and only affected certain apoptotic 
proteins in certain tissues.  Doxorubicin decreased caspase-3 leveles in the 3-day SOL, 
and increased cleaved caspase-3 levels in the 3-day EDL. 
Creatine’s Effect on Apoptotic Proteins 
Creatine monohydrate (Cr) is perhaps one of the most widely used nutraceuticals 
ingested in an attempt to improve high intensity athletic performance. A large amount of 
research has been done on Cr supplementation in efforts to delineate its sport-specific 
effects. It is hypothesized that Cr acts through a number of pathways and appears to be 
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most effective in short-term, high-intensity physical activities.  However, the past decade 
has shown that the use of Cr for therapeutic purposes has received increasing attention 
(Gualano et al., 2009).  Creatine supplementation is beneficial in a large number of 
muscular, neurological, and cardiovascular diseases (Bender et al., 2007; Felber et al., 
2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al., 
2001; Neubauer et al., 1999; Sharov et al., 1987; Stout et al., 2001; Tarnopolsky et al., 
2004; Tarnopolsky, 2007; Vorgerd et al., 2000; Wyss & Schulze, 2002), however, less 
documented are the effects of Cr on Dox-induced skeletal muscle dysfunction, and there 
is a lack of research on possible mechanisms leading to improvements in Dox-induced 
skeletal muscle dysfunction.  One such mechanism may be creatine’s ability to modulate 
apoptosis.    
Rahimi et al. (2015) examined the effects of creatine monohydrate 
supplementation on apoptotic markers and found that creatine monohydrate 
supplementation prevented exercise induced apoptosis, as measured by decreases in p53 
concentration.  It is well known that p53 plays a significant role in regulating apoptosis 
by affecting the expression of apoptotic peptidase activating factor-1 and by altering 
mitochondrial membrane potential (Haldar et al., 1994; Moll & Zaika, 2001).  Rahimi et 
al. (2015) suggested that the increase in oxidative stress with aerobic exercise signals 
p53, which in turn triggered the p53 dependent apoptotic pathway to preserve genomic 
intensity and cellular homeostasis.  Although not directly measured, Rahimi et al. (2015) 
suggest that Cr may act as an antioxidant, scavenging ROS.  This then reduces the ROS-
induced signaling of p53, which was one of the findings of that particular study, reduced 
serum p53 concentration with Cr supplementation.  Sheikholeslami-Vatani and Faraji 
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(2018) also found that creatine supplementation reduced apoptotic markers with exercise, 
reducing caspases (-3 and -9), p53, and Bax when compared to placebo.   
As with Rahimi et al. (2015), Sheikholeslami-Vatani and Faraji (2018) suggest 
that although not directly measured, the reduction in the apoptotic markers may have 
been due to the ability for Cr supplementation to reduce ROS production which reduced 
the signaling of the apoptotic caspases (-3 and -9) and p53.  Lastly, in exercise-induced 
apoptosis, Cr supplementation reduced lipid peroxidation and glutathione peroxidase 
activity, and attenuated oxidative DNA damage with the suggested mechanisms being the 
potential ROS scavenging capabilities (Basta et al., 2006; Mirzaei et al., 2013; Rahimi, 
2011).  Although not examined in skeletal muscle, Zhu et al. (2004) showed that in focal 
cerebral ischemia, Cr supplementation either directly or indirectly inhibited cytochrome c 
release and downstream caspase-3 activation. Equally, Cr supplementation has been 
shown to reduce caspase-3/7 activation in HL-1 cardiomyocytes (Santacruz et al., 2015). 
In summary, Cr supplementation can reduce markers of apoptosis in a variety of 
conditions.  Although the mechanisms are not elucidated, it is postulate that Cr acts an 
antioxidant, scavenging free radicals, and reducing their quantity which ultimately 
reduces apoptosis.   
In the current study, rats were fed one of two experimental diets, C1 and C2.  
Creatine 1 was a 2% Cr supplemented diet for four weeks, and Creatine 2 was one week 
of a 4% Cr supplemented diet, followed by three weeks of a 2% Cr supplemented diet.  
Based on human studies examining Cr supplementation (Casey & Greenhaff, 2000; 
Greenhaff, Bodin, Soderlund, & Hultman, 1994; Stout et al., 2001), it has been 
determined that Cr supplementation has to occur for long enough to raise Cr 
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concentration levels enough for Cr to exert its ergogenic effects.  In light of this research, 
the current study employed a Cr feeding protocol that was hoped to be long enough (four 
weeks) to raise Cr levels in the skeletal muscle of the animals.  Equally, the current study 
implemented a loading phase, with 4% Cr feeding for a week, followed by 2% Cr feeding 
for three weeks.  Lastly, the C2 diet attempted to increase the amount of free Cr stores 
(i.e., Cr not bound to a phosphate).  Research has shown that Cr can function as an 
antioxidant, decreasing the free radical load on the cell (Basta et al., 2006; Mirzaei et al., 
2013; Rahimi et al., 2015).  In these studies, it is free Cr that can function as an 
antioxidant, and the current study attempted to increase free Cr stores via the C2 diet.   
The overall findings were that Cr feeding, had the greatest impact on 1-day 
apoptotic proteins.  At the 1-day time point, Cr increased cleaved PARP levels in the 
EDL and SOL, decreased caspase-3 levels in the EDL, and decrease cleaved caspase-3 
levels in the SOL and DIA.  The only effect observed at the 3-day time point was Cr 
increased cleaved caspase-3 levels in the EDL.   
Cleaved PARP levels increased with Cr feeding in the EDL and SOL.  A search 
of the literature failed to show that Cr supplementation would have an affect on cleaved 
PARP.  An increase in cleaved PARP means the cell is going to be killed, via apoptosis, 
and as mentioned, there is no research suggesting Cr triggers apoptosis.  Specifically, the 
highest levels of cleaved PARP were in the C2-Dox group (although not significantly 
higher than in the Con-Dox group) and C2-Sal group had significantly higher cleaved 
PARP levels than in the C1-Sal group.  As described in previous sections, the current 
method used to measure cleaved PARP may not be sensitive enough and may be 
impacting our assessment of the effects of Cr feeding on cleaved PARP in the EDL, SOL, 
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and DIA.  Therefore, the current results for cleaved PARP should be interpreted with 
caution.   
In the 1-day EDL, Cr feeding decreased caspase-3 levels, with the highest level 
observed in the C1-Dox and lowest level in the C2-Dox.  A higher level of caspase-3 
suggests that apoptosis is not very active, with lower levels of caspase-3 indicating that 
caspase-3 is being cleaved and converted to cleaved caspase-3 which is a strong driver of 
apoptosis in the cell.  The highest caspase-3 values were observed in the C1-Dox 
condition, suggesting that the C1 feeding may have protected the cell from Dox-induced 
cleaving of caspase-3.   As stated with cleaved PARP, research does not indicate that Cr 
supplementation by itself, would be a stimulator of apoptosis in the cell, and possilby, in 
a condition where there is an increase in free radicials, Cr supplementation may decrease 
cleaved caspase-3 levels in the cell.  Based on this, one would postulate that cleaved 
capase-3 levels, an indicator that apoptosis is occurring in the cell, would stay the same 
with Cr feeding.  This was the case in the 1-day SOL and DIA, where Cr feeding 
decreased cleaved caspase-3 levels.  However, in the 3-day EDL, Cr feeding had the 
greatest effect on cleaved caspase-3 levels.   
In the 3-day EDL, cleaved caspase-3 levels were significantly higher in C1-Sal, 
C1-Dox, and C2-Sal when compared to Con-Sal. Surprising is the significant increase in 
cleaved caspase-3 levels in the C1-Sal and C2-Sal when compared to Con-Sal.  This 
suggests that Cr feeding somehow increased cleaved caspase-3 levels, and potentially 
apoptosis in the cells.  These results do not agree with the literature, as Cr has not been 
shown to drive apoptosis, especially in tissues treated with a substance similar to Dox.   
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In the 3-day EDL, cleaved caspase-3 levels were significantly higher in the C1-
Dox and C2-Sal groups when compared to Con-Dox.  Again, this suggests that Cr 
feeding increased cleaved caspase-3 levels and may indicate that Cr increases apoptosis, 
which is not supported in the literature.  
Lastly, there was an interaction in the 3-day EDL.  Cleaved caspase-3 levels were 
observed to be higher in the C1-Dox group when compared to the C2-Dox group.  This 
agrees with the research that shows free Cr can act as an antioxidant, scavenging free 
radicals that Dox administration has been shown to increase, decreasing the triggering of 
apoptosis and subsequent increase in caspase-3 activation to cleaved caspase-3 (Rahimi 
et al., 2015; Sheikholeslami-Vatani & Faraji, 2018).    
Overall, there are several findings in the current study that do not agree with the 
hypothesis or research that demonstrate that Dox drives apoptosis in cells.  Doxorubicin 
administration had very little effect on apoptotic proteins, especially in the 3-day tissue, 
with a drug effect only being observed in 3 conditions (cleaved PARP, 3-day DIA; 
caspase-3, 3-day SOL; cleaved caspase, 3-day EDL), and the decrease in cleaved PARP 
levels in the 3-day DIA do not agree with the literature.  Equally, Cr feeding seemed to 
increase levels of apoptotic proteins, suggesting that it may somehow drive or trigger cell 
damage, which is nowhere supported in the literature.  Regarding cleaved PARP, it is 
likely that the Western blot technique used to detect PARP activity in the current study, 
may have not been the most sensitive method to tease out the possibly subtle changes in 
PARP with Cr feeding and Dox administration.   
The PARP gene is expressed constitutively, meaning it is expressed at a constant 
level in the cell, and measuring expression of mRNA or protein will not accurately assess 
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its activation.   Research has shown that the response of eukaryotic cells to DNA damage 
is the catalytic activation of PARP.  When activated PARP splits nicotinamide adenine 
dinucleotide (NAD+) to produce ADP-ribose, nicotinamide, and a proton (Affar, Shah, 
Dallaire, Castonguay, & Shah, 2002).  The then activate PARP strings together the ADP-
ribose (forms polymer of ADP-ribose or pADPr) which binds and modifies cellular 
proteins (Rouleau, Patel, Hendzel, Kaufmann, & Poirier, 2010).   Based on this, the most 
accurate and sensitive method to detect the catalytic activation of PARP is by 
demonstrating the consequences of its catalytic reaction.  The catalytic reaction results in 
the consumption of the substrate nicotinamide adenine dinucleotide (NAD+) and 
formation of polymer of ADP-ribose (pADPr or PAR), nicotinamide, and protons.   
As an alternative to the techniques used in the current study to quantify changes in 
PARP levels, techniques employed by Ueno et al. (2006) may be a more appropriate 
option.  Ueno et al. (2006) suggests Western blotting of pADPr modified proteins, which 
have a signal of 110 to 250 kDa are to be probed.  The method for preparing the tissue 
differs, in that urea-SDS buffer is used in place of RIPA buffer.  Along with Western 
blot, quantification of NAD+ levels should be used to assess PARP activation.  The 
lowering of NAD+ substrate levels in response to DNA damage is an accurate way to 
represent the activation of PARP (Vodenicharov, Ghodgaonkar, Halappanavar, Shah, R. 
G., & Shah, G. M., 2005).  In closing, the PARP results in the current study may not 
reveal the entire findings.  The PARP results may be limited by the use of a less than 
ideal laboratory technique and had the techniques described by Ueno et al. (2006) been 
employed, additional drug and diet effects may had been uncovered. 
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The current study demonstrated very little drug effect on cleaved caspase-3 in any 
tissue, no matter the time point.  The caspases are collectively a family of proteases and 
are the central executioners of the apoptotic pathway.  The main methods designed to 
detect activation of caspases are (1) measure specific synthetic substrates designed to 
contain flurogenic or chromogenic leaving groups after the aspartate residue; (2) Western 
blot using an antibody specific to the active caspase; (3) Western blot caspase-specific 
cleaved products (PARP, cytokeratin-18, and lamin A); (4) immunocyto-chemical 
localization of an activated caspase using antibodies specific to the caspase; (5) 
fluorochrome-labeled inhibitors of caspases as affinity ligands that bind to the active 
center of the active caspase; and (6) colored fluorescent protein covalently linked to a 
small peptide that target a caspase (Darzynkiewicz, Pozarowski, Lee, & Johnson, 2011; 
Tawa, Tam, Cassady, Nicholson, & Xanthoudakis, 2001).  Based on the research above, 
unlike the case of cleaved PARP, the Western blot method has been shown to be an 
effective method for quantifying cleaved caspase-3 expression.  Another possible reason 
for not seeing elevated levels of cleaved caspase-3 in Dox treated animals is that when 
the EDL, SOL, and DIA are extracted, they are flash frozen in liquid nitrogen and then 
stored in a -80°C freezer.  This essentially freezes the cellular state of the tissue in time.  
Research shows that caspase levels can vary in the cell, rising and falling, and that this 
undulation can differ based on tissue and on the type of caspase (Liu et al., 2017).  It is 
possible that what was observed in the current study is not the actual level of apoptotsis 
in the muscle, but the levels of these caspases in the moment of time we extracted the 
tissue. The caspase levels could differ if we extracted the tissues earlier or later, and their 
levels may not accurately represent what effect Cr and Dox have on their expression.  
	 78 
	
Equally, muscles from the animals were not all extracted at the exact same moment, and 
this could explain why the caspase expression fluctuated from tissue to tissue and had no 
disernable pattern from 1-day to 3-day.  Worth mentioning is the effect Dox has on other 
types of muscle tissue, specifically cardiac muscle tissue.   
Doxorubicin’s major adverse effect is cardiotoxicity, which is the number one 
factor that limits its use, and can be fatal (Jordon, 2002; Takemura & Fujiwara, 2007).  
Doxorubicin accumulation is tissue dependent, with higher rates of accumulation 
observed in cardiac tissue when compared to skeletal muscle tissue (Hayward et al., 
2013).  This is possible due to Dox accumulating primarily in the mitochondria and 
cardiac tissue has higher amounts of mitochondria when compared to both type I and type 
II skeletal muscle fibers (Hayward et al., 2013).  The higher the Dox dose, the greater the 
incident of cardiotoxicity (Lefrak, Pitha, Rosenheim, & Gottlieb, 1973; Hayward & 
Hydock, 2007).  The main effects Dox treatment produces in the heart is cardiomyopathy, 
referred to as doxorubicin cardiomyopathy.  Interestingly, the mechanisms of Dox-
cardiotoxicity differ from Dox-tumor toxicity, in that the cardiotoxicity results from 
increased oxidative stress, as evident from increased reactive oxygen species and lipid 
peroxidation (Singal, Deally, & Weinberg, 1987).  There is significant evidence that Dox 
induces apoptosis of cardiomyocytes (Wang, Ma, Markovich, Chen, & Wang, P. H., 
1998; Kotamraju, Konorev, Joseph, & Kalyanaraman, 2000).  The increase in oxidative 
stress increases formation of hydogren peroxide and superoxide, which activates p53-
induced apoptosis and ultimately Dox-cardiomyopathy (Wang et al., 1998; Kotamraju et 
al., 200).   
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Lastly, the animal characteristic data showed a statistically significant drug effect 
in both the 1-day and 3-day EDL, SOL, and DIA tissue mass. This illustrates that the Dox 
treated animals (both 1-day and 3-day) lost tissue mass, which means some form of cell 
death was occurring, which means cleaved caspase-3 and cleaved PARP levels would 
increase.  Based on this observation, I conclude the laboratory method for measuring 
PARP levels and that the tissues extraction markers a point in time, are the best 
explanations to somewhat describe the drug effects results of the current study.   
The diet effects results are equally hard to explain.  The most confusing are: Cr 
feeding increased cleaved PARP levels in the 1-day EDL and SOL, and increased cleaved 
caspase-3 levels in the 3-day EDL.  As stated in multiple sections, research has not 
demonstrated Cr supplementation to increase cleaved PARP or cleaved caspase-3 levels 
in the tissue, cell culture.  Interestingly, research has showed that Cr supplementation is 
beneficial in a large number of muscular, neurological, and cardiovascular diseases 
(Felber et al., 2000; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al., 2001; 
Sharov et al., 1987; Stout et al., 2001). Equally, the animal characteristic data showed no 
significant diet effect on EDL, SOL, or DIA tissue mass at either the 1-day or 3-day time 
point.  Based on previous Cr research and the animal characteristic data, an explanation 
for the current findings that Cr supplementation may increase apoptosis in the EDL and 
SOL has remained elusive.  
Doxorubicin and Creatine’s Effect on 
Creatine Concentration 
 
Creatine, or methylguanidine-acetic acid, is a naturally occurring compound 
synthesized from arginine, glycine, and methionine in humans in the liver and pancreas 
(Bloch & Schoenheimer, 1941; Walker, 1979). Creatine is found in meat and found 
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principally in skeletal muscle, and in its free and phosphorlayted form plays a pivotal role 
in the regulation and homeostasis of skeletal muscle energy metabolism (Bessman & 
Fonyo, 1966; Bessman & Geiger, 1981; Meyer, Sweeney, & Kushmerick, 1984; 
Walliman, Wyss, Brdiczka, Nicolay, & Eppenberger, 1992).   In an average 70 kg adult, 
the total creatine pool in the body amounts to about 120 g and is continuously degraded 
to creatinine, and excreted in the urine at a rate of about 2 g/day (Walker, 1979).  
Creatine replishment is a combination of dietary intake and endogenous systhesis and 
most of the total creatine pool is contained in skeletal muscle, with 65% in a 
phosphorylated form called phosphocreatine (Casey, Constantin-Teodosiu, Howell, 
Hultman, & Greenhaff, 1996a; Hunter, 1922; Walker, 1979).   
Human skeletal muscle is composed of several fiber types that differ substantially 
in functional and metabolic characteristics.  Fiber types range from type I, slow-twitch 
fiber (example, soleus and diaphragm), to the type II, fast-twitch fiber (e.g., extensor 
digitorum longus).  Specifically, creatine metabolism differs between fiber type, with 
type II fibers utilizing phosphocreatine (thus reducing free Cr to resynthesize pCr) at 
greater rates than type I fibers (Greenhaff, Nevill, & Soderlund, 1994; Soderlund, 
Greenhaff, & Hultman, 1992; Tesch, Thorsson, & Fujitsuka, 1989).   In rodents, total 
creatine concentration of type II, fast-twitch muscle is 45% greater than that of type I, 
slow-twitch muscle, and that the increase in phosphocreatine concentration after creatine 
supplementation is greater in type II fibers with free creatine concentration greater in type 
II fibers (Casey, Constantin-Teodosiu, Howell, Hultman, & Greenhaff, 1996b; Greenhaff, 
Bodin, & Casey, 1996). 
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It has been shown that the ingestion of creatine can increase the total creatine 
(free creatine + phosphocreatine) levels in skeletal muscle.   Harris, Soderlund, and 
Hultman (1992) found that 5 g creatine taken 4-6 times/day for several consecutive days 
increased the total creatine concentration of human skeletal muscle by an average of 25 
mmol/kg dry mass, with 30% of which occurred in phosphorylated form as 
phosphocreatine.  Equally, Greenhaff et al. (1993), found that ingestion of 20-30 g Cr/day 
for several days can lead to a >20% increase in human skeletal muslce total Cr content.  
However, in human studies, the data illustrate that there is a large variation in creatine 
uptake between individuals after creatine supplementation, from 6 – 38 mmol/kg dry 
mass (Casey et al., 1996a).   It has been suggested that a maintenance dose of 2 g/day 
after the 20-30 g/day for several days, will maintain a high total creatine concentration in 
the muscle for a period of 28 days (Hultman, Soderlund, Timmons, Cederblad, & 
Greenhaff, 1996).  Lastly, in humans, supplementing with dose larger than 30 g/day 
shows no evidence of any potentiating effect on muslce creatine uptake (Harris et al., 
1992; Hultman et al., 1996).  In fact, a consistent finding from several studies is that there 
appears to be a definable upper limit to the intramuscular total creatine concentration of 
160 mmol/kg dry mass, and once this limit is reached, further supplementation will only 
result in increased excretion of creatine in the urine (Casey et al., 1996b; Harris et al., 
1992).   
The assay used in the current study quantified total Cr concentration in the 
samples.  This includes free Cr (creatine not bound) and Cr bound to a phosphate.  This is 
a limitation, in that there is no way of determining if the drug and/or diet interventions 
effected the concentrations of the unbound Cr or Cr bound to a phosphate.  Presently,  Cr 
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concentration did not increase in the EDL, SOL, or DIA, at either time point.  In fact, the 
only diet effect was observed in the 3-day EDL, with there being an overall lower Cr 
concentration with Cr feeding.  Equally, there was a drug effect in the 3-day EDL, with 
lower Cr concentrations observed in rodents administered Dox.  Taken together, the diet 
effect observed in the 3-day EDL could be influenced by the fact that the Cr-Dox animals 
had significantly lower Cr concentrations.  The decrease in Cr concentration in the Cr-
Dox animals could impact the overall observation that diet decreases Cr concentration.  
The only other drug effect was observed in the 1-day SOL, with Dox administration 
decreasing Cr concentration levels.  There was neither a drug or diet effect observed in 
the DIA at either time point.  Equally, no main effects were observed in the 1-day EDL or 
3-day SOL.  The decrease in total Cr concentration with Dox administration is not 
surprising, although, the exact mechanism(s) that may have caused this is speculative.  
One potential mechanism could be a reduction in creatine transport into all three skeletal 
muscles via reduced quantity of cell membrane creatine transporter.  
Creatine, which is synthesized in the kidneys, must be transported into tissue 
(e.g., skeletal muscle) via creatine transporter which is embedded into the plasma 
membrane of the cell (Guerrero-Ontiveros & Wallimann, 1998).  Creatine transporters 
are found in rat cardiac, skeletal muscle (quadriceps, soleus, and gastrocnemius), kidney, 
and brain (Neubauer et al., 1999).  Additionally, the highest expression of the creatine 
transporter is found in the heart, and skeletal muscle, specifically in the soleus (Guerrero-
Ontiveros & Wallimann, 1998; Murphy et al., 2001).  Research by Darrabie et al. (2012), 
found a significant and irreversible decrease in creatine transport after an incubation with 
50 – 100 nmol/l doxorubicin.  Similar studies have shown Dox to decrease 
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phosphocreatine (pCr) and ATP, as much as 70% (Maslov et al., 2010; Ohhara, Kanaide, 
& Nakamura, 1981; Seraydarian, Artaza, & Goodman, 1977).  Interestingly, kinetic 
analysis showed that the decrease in creatine transport was not due to Dox-induced 
increased cell death, but rather to a decrease in Cr Vmax, Km, and creatine transporter 
protein content (Darrabie et al., 2012).  These results indicate that Dox may alter the 
affinity of the creatine transporter for Cr and/or the stability of the creatine transporter 
due to potential oxidative damage of sensitive amino acids in the transporter (Darrabie et 
al., 2012).  In the current study the drug effect in the 1-day SOL and 3-day EDL could be 
due to creatine transporter dysfunction resulting in decreased Cr transport from the blood 
into the EDL and DIA.  As stated previously (Murphy et al., 2001), creatine transporter 
expression is higher in the SOL (when compared to the EDL and DIA) and this may have 
led to higher level of Cr transport into the SOL.  This could be an explanation as to the 
decrease in Cr concentration observed in the EDL and not the SOL.  In regards to the 1-
day EDL, SOL and DIA, it is possible there was not enough time for Dox to damage the 
creatine transporter to a significant level to affect creatine transport and subsequent Cr 
concentration in the 1, 3-day DIA, 1-day EDL, and 3-day SOL   
Of most interest was the effects of Dox and Cr on Cr concentration levels in the 1-
day EDL, 3-day SOL, and 1, 3-day DIA.  No effects were observed in these muscle 
tissues.  This means Cr feeding did not increase or decrease creatine concentration, nor 
did Dox.  Research has shown Cr concentration to differ with fiber type, with free 
creatine concentration greater in type II fibers (Casey et al., 1996b; Greenhaff et al., 
1996).  The DIA, which is a mixture of type I and type II fibers, had similar effects as the 
type II EDL.  It could be that in the above mentioned skeletal muscles there was an 
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increased level of Dox-induced free radical production and free Cr was acting as an 
antioxidant,  scavenging free radicals in these muscles.  This could have resulted in lower 
amounts of free Cr in these skeletal muscles, thus decreasing total Cr concentration 
observed in these muscles, and not reflecting a statistical change in Cr concentration with 
Cr feeding.  To further support this, cleaved PARP and cleaved caspase-3 levels did not 
change with Dox treatment in the 3-day SOL, and cleaved caspase-3 levels decreased 
with Dox in the 3-day EDL.  This could suggest that at the 3-day time point Dox may 
effect the type II EDL differently than the type I SOL, resulting in higher Dox-toxicity in 
the EDL than SOL.  This possibly increased activity could have lead to increased use of 
free Cr as an antioxidant, resulting in the observed reduction in total Cr concentration in 
the 3-day EDL.   Lastly, the lack of observable increase in total Cr concentration with Cr 
feeding in the EDL, SOL, and DIA in the C1-Sal, and C2-Sal groups at either time point 
remains unknown. 
Creatine Concentration and Apoptotic 
Proteins 
 
In the current study Dox had the greatest effect on decreasing Cr concentration in 
the 1-day SOL and 3-day EDL.  Subsequently, the only effect observed in the 3-day EDL 
was increased cleaved caspase-3 levels with both Dox and Cr.  The only effect observed 
in the 3-day DIA was a decrease in cleaved PARP with Dox.  Creatine feeding only 
decreased Cr concentration in the 3-day EDL.  In the 1-day EDL, drug and diet increased 
cleaved PARP levels; diet decreased caspase-3 levels, and there was no change in cleaved 
caspase-3 levels.  The 1-day SOL, in which there was a drug or diet effect on Cr 
concentration observed, had an increase in 1-day cleaved PARP levels with drug and diet, 
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and a decrease in cleaved caspase-3 with Cr feeding.  Equally, caspase-3 levels were 
lower in the 3-day Sol with Dox.   
 In closing, this is the first report examining the effects of two types of Cr feeding 
and Dox on the apoptotic marker; cleaved PARP, caspase-3, and cleaved caspase-3 in 
three separate skeletal muscles, at two different time points.  Both Cr feeding and Dox 
administration affected Cr concentration differently depending on the time point and 
tissue.  Apoptotic protein levels were affected by both Cr and Dox, and levels varied 
depending on the protein, tissue, and time point.  Overall, Dox administration and Cr 
feeding affect Cr concentration and apoptotic protein levels in the EDL, SOL, and DIA at 
both the 1-day and 3-day time points.   
Moving forward, the results obtained indicate that Cr has some effect on skeletal 
muscle treated with Dox.  The current study examined the apoptotic pathway, and 
previous research our lab has examined myogenic regulatory factors, and these findings 
only begin to attempt to explain how Cr may be affecting Dox-induced myotoxicity.  In 
response, it is important to continue investigating Cr and other nutraceutical supplements 
that may help reduce the negative impacts of chemotherapy on cancer patients.  It is 
equally important to find alternative treatments that have low side effects and are safe to 
take along side traditional cancer treatments.  The current findings are encouraging, that 
there are compound (such as Cr) that exist that are cheap, safe, and easy to ingest, that 
may improve the quality of life for cancer patients, or possibly the quality of life for 
patients being treated for other diseases.  In light of this, as research to find better 
treatments increase (with potentially greater unpleasant, or deadly side effects), so should 
research for treatments to combat the side effects of the new treatments increase.  This 
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approach would ultimately lead to a better quality of life for the patient and possibly 
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1-day EDL apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP ‡ † 0.84 ± 0.05 1.07 ± 0.08 * 0.722 ± 0.03 1.03 ± 0.03 * 1.06 ± 0.03 *+  1.24 ± 0.07 * 
Caspase-3 † 0.28 ± 0.06 0.21 ± 0.02 0.22 ± 0.02 0.29 ± 0.04 0.17 ± 0.01 0.15 ± 0.01 
Cleaved caspase-3 0.33 ± 0.08 0.35 ± 0.10 0.22 ± 0.05 0.38 ± 0.10 0.25 ± 0.03 0.22 ± 0.07 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
‡ = signficant drug effect (p<0.05) 
† = significant diet effect (p<0.05) 
* = significantly different from C1-Sal  







1-day SOL apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP ‡ 0.83 ± 0.05 * 1.12 ± 0.15 0.76 ± 0.15 * 0.67 ± 0.08 * 0.86 ± 0.06 * 1.64 ± 0.33 
Caspase-3 0.19 ± 0.04 0.16 ± 0.02 0.09 ± 0.02 0.14 ± 0.02 0.12 ± 0.02 0.15 ± 0.04 
Cleaved caspase-3 †  1.33 ± 0.15 1.48 ± 0.19 1.06 ± 0.19 0.90 ± 0.12 1.07 ± 0.08 1.15 ± 0.21 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
‡ = signficant drug effect (p<0.05) 
† = significant diet effect (p<0.05) 















1-day DIA apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP 0.43 ± 0.04 0.50 ± 0.07 0.39 ± 0.05 0.54 ± 0.04 0.52 ± 0.04 0.45 ± 0.05 
Caspase-3 0.13 ± 0.02 0.11 ± 0.02 0.09 ± 0.02 0.14 ± 0.02 0.12 ± 0.02 0.08 ± 0.01 
Cleaved caspase-3 † 0.08 ± 0.01 0.07 ± 0.01 0.04 ± 0.01 0.07 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  


















3-day EDL apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP 0.76 ± 0.05 0.70 ± 0.05 0.81 ± 0.08 0.82 ± 0.08 0.75 ± 0.07 0.63 ± 0.05 
Caspase-3 1.39 ± 0.16 1.06 ± 0.13 1.07 ± 0.17 1.06 ± 0.16 1.00 ± 0.17 1.02 ± 0.19 
Cleaved caspase-3 †‡ 0.04 ± 0.01  0.10 ± 0.03 0.31 ± 0.03 * 0.52 ± 0.08 *+ 0.37 ± 0.08 *+ 0.16 ± 0.03 ° 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
† = significant diet effect (p<0.05) 
‡ = significant drug effect (p<0.05) 
Significant interaction in the EDL cleaved caspase 3 (p<0.05) 
*  = significantly different from Con-Sal 
+ = significantly different from Con-Dox 






3-day SOL apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP 0.63 ± 0.06 0.66 ± 0.03 0.70 ± 0.04 0.64 ± 0.04 0.76 ± 0.06 0.63 ± 0.05 
Caspase-3 ‡ 1.31 ± 0.15 0.94 ± 0.05 1.06 ± 0.06 0.92 ± 0.09 1.01 ± 0.10 0.98 ± 0.11 
Cleaved caspase-3 1.13 ± 0.10 1.02 ± 0.06 1.24 ± 0.05 1.18 ± 0.09 1.34 ± 0.13 1.32 ± 0.19 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  







3-day DIA apoptotic protein levels. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
Cleaved PARP ‡ 0.64 ± 0.07 0.38 ± 0.06 * 0.56 ± 0.03 0.51 ± 0.05 0.57 ± 0.05 0.42 ± 0.05 
Caspase-3 0.29 ± 0.11 0.30 ± 0.14 0.26 ± 0.08 0.20 ± 0.07 0.10 ± 0.01 0.10 ± 0.02 
Cleaved caspase-3 0.16 ± 0.03 0.09 ± 0.01 0.12 ± 0.02 0.09 ± 0.01 0.09 ± 0.02 0.11 ± 0.02 
Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.  
‡ = significant drug effect (p<0.05). 






1-day creatine concentration. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
EDL (M)  0.10 ± 0.04  0.06 ± 0.01 0.05 ± 0.03 0.06 ± 0.03 0.08 ± 0.02 0.05 ± 0.03 
SOL (M) † 0.09 ± 0.01 0.07 ± 0.01 0.09 ± 0.01 0.08 ± 0.03 0.10 ± 0.02 0.06 ± 0.03 
DIA (M) † 0.18 ± 0.08 0.13 ± 0.09 0.15 ± 0.04 0.15 ± 0.06 0.12 ± 0.04 0.12 ± 0.04 
Note. EDL = extensor digitorum longus; SOL = soleus; DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control 
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, 
creatine 2 doxorubicin, n=10. Values are means ± SEM.  

















3-day creatine concentration. 
 Con-Sal Con-Dox C1-Sal C1-Dox C2-Sal C2-Dox 
EDL (µM/µg) † ‡  0.09 ± 0.02  0.05 ± 0.01 * 0.06 ± 0.01 * 0.05 ± 0.01 * 0.07 ± 0.02 0.03 ± 0.02*+ 
SOL (µM/µg) 0.10 ± 0.04 0.09 ± 0.009 0.09 ± 0.03 0.09 ± 0.007 0.09 ± 0.04 0.07 ± 0.04 
DIA (µM/µg)  0.18 ± 0.10 0.14 ± 0.06  0.16 ± 0.07 0.18 ± 0.05  0.21 ± 0.11 0.11 ± 0.06  
Note. EDL = extensor digitorum longus; SOL = soleus; DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control 
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, 
creatine 2 doxorubicin, n=10. Values are means ± SEM.  
† = significant diet effect (p<0.05). 
‡ = significant drug effect (p<0.05). 
* = significantly different than Con-Sal (p<0.05). 
+ = significantly different than C2-Sal (p<0.05). 
	
	
 
